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The  2011  EPA  trichloroethylene  (TCE)  IRIS  assessment,  used  developmental  cardiac  defects  from  a  con-
troversial  drinking  water  study  in  rats  (Johnson  et  al. [51]),  along  with  several  other  studies/endpoints  to
derive reference  values.  An updated  literature  search  of  TCE-related  developmental  cardiac  defects  was
conducted.  Study  quality,  strengths,  and  limitations  were  assessed.  A  putative  adverse  outcome  pathway
(AOP)  construct  was  developed  to explore  key  events  for  the most  commonly  observed  cardiac  dys-
morphologies,  particularly  those  involved  with  epithelial-mesenchymal  transition  (EMT) of endothelial
origin  (EndMT);  several  candidate  pathways  were  identiﬁed.  A  hypothesis-driven  weight-of-evidenceCE
ardiac
alformations
OP
analysis  of  epidemiological,  toxicological,  in vitro,  in  ovo,  and  mechanistic/AOP  data  concluded  that  TCE
has  the  potential  to  cause  cardiac  defects  in  humans  when  exposure  occurs  at sufﬁcient  doses  during
a  sensitive  window  of  fetal  development.  The  study  by Johnson  et  al. [51]  was  reafﬁrmed  as  suitable
for  hazard  characterization  and  reference  value  derivation,  though  acknowledging  study  limitations  and
uncertainties.
Published by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Trichloroethylene (TCE), CAS No. 79-01-6, is a volatile chemi-
al and widely used chlorinated solvent that is frequently found in
round water and in soil at contaminated sites across the U.S. TCE
anks 16th among hazardous substances most commonly found
t facilities on the federal National Priorities List [4]. At sites where
roundwater is contaminated and depending upon site-speciﬁc cir-
umstances, TCE exposures and accompanying human health risks
ay  arise from: (1) movement of TCE vapors from subsurface loca-
ions into the indoor air of overlying and nearby buildings (i.e.,
apor intrusion) [5]; and/or (2) use of groundwater as a source
f drinking water, process water, or irrigation water. A number
f health effects have been observed after exposure to TCE dur-
ng development, e.g., decreased fetal survival, impaired growth,
lterations in immune and nervous system function, and structural
efects, including ocular and cardiac malformations [16]. Here we
eport on a focused review of the published literature, conducted
o update the information and critically evaluate the available data
elevant to the potential for cardiac defects resulting from devel-
pmental exposures to TCE. This effort was initiated because of
oncerns raised about study quality and application of the reference
alue to short term and pregnancy exposure scenarios.
EPA completed an IRIS Toxicological Review of TCE in September
011 [87]. The most sensitive types of noncancer health effects
dentiﬁed in this assessment were developmental, renal, and
mmunological. A reference concentration (RfC)2 of 0.0004 ppm
0.4 ppb or 2 g/m3) is derived in U.S. EPA [87], based on route-to-
oute extrapolated results from oral studies for the critical effects
f heart malformations in rats and immunotoxicity in mice, fur-
her supported by route-to-route extrapolated results from an oral
tudy of nephropathy in rats. The reference dose (RfD) for non-
ancer effects of 0.0005 mg/kg-day is based on the critical effects
n oral studies of heart malformations in rats, adult immunolog-
cal effects in mice, and developmental immunotoxicity in mice.
he RfD is further supported by results from an oral study for the
ffect of toxic nephropathy in rats and route-to-route extrapolated
2 A reference concentration (RFC) or dose (RfD) is an estimate of a continuous
nhalation exposure (daily oral exposure) for a chronic duration (up to a lifetime) to
he human population (including sensitive subgroups) that is likely to be without
n  appreciable risk of deleterious effects during a lifetime. .  . .  . . . .  . . .  . . . . .  .  . . . . .  . .  .  .  . . .  . . .  . . . . . . .  .  . . .  .  . . . .  .  .  . . . . .  . . . . . . .  .  .  .  . . .  .  . .  . . . .  .  356
results from an inhalation study for the effect of increased kidney
weight in rats ([87]; pages 6–43).
After the ﬁnal IRIS document was  released, EPA and others real-
ized that because fetal adverse outcomes could potentially result
from short-term exposures or peaks in exposure during pregnancy,
one of the two endpoints used to derive the RfC (the fetal cardiac
defects) is particularly important when evaluating whether TCE
exposure poses an immediate potential hazard and whether peak
exposures are a potential health concern. A study by Johnson et al.
[51], which reports the results of research on TCE in drinking water,
including the ﬁndings of Dawson et al. [20], is included in the group
of studies on which the reference values are based in the 2011 IRIS
assessment, and is one of several lines of evidence regarding the
hazard potential for developmental toxicity of TCE. Concerns have
been raised about the Johnson et al. [51] study and EPA’s use of this
study for risk evaluation [1,90,38]. Speciﬁc needs to resolve these
concerns include: (1) a systematic evaluation of study quality; (2)
more details in the description of the study design (e.g., the source
of concurrent controls); (3) a reexamination of the dose-response
relationship for cardiac defects; and (4) an evaluation of the study
results in light of other studies that did not observe cardiac defects
after in utero exposures. In addition, concerns have been raised
regarding the interpretation of the epidemiological database for
cardiac defects associated with TCE exposures [13,1,90,38].
An updated literature search and analysis of the developmen-
tal cardiac toxicity data for TCE was conducted to address the
identiﬁed issues and to provide a focused, rigorous, systematic
scientiﬁc review of the available data on associations between
exposure to TCE and fetal cardiac defects. The scope of this update
and analysis was limited to the fetal cardiac defects observed
following gestational exposures to TCE and/or its oxidative metabo-
lites, dichloroacetic acid (DCA) and trichloroacetic acid (TCA),
which have been speciﬁcally associated with cardiac malforma-
tions in rats [51,49,20,27,79,78], and does not include an update on
other developmental effects after TCE exposure, i.e., fetal growth
retardation, embryolethality, ocular malformations, developmen-
tal neurotoxicity, and developmental immunotoxicity. This update
of the fetal cardiac effects includes (1) a systematic search to iden-
tify any recently published literature; (2) a detailed evaluation
of the available data; (3) a hypothesis-driven assessment of the
weight of evidence (evidence integration) for the association of TCE
exposures with cardiac malformations; (4) a reexamination of the
dose-response relationship for cardiac malformations; and (5) a
transparent description of the evaluation. This process is aligned
ive Tox
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ith the [64] recommendations for systematic review, evidence
ntegration (weight-of-evidence) evaluation, and presentation of
nformation to increase transparency.
. Materials and methods
.1. Literature search update
A systematic literature search was conducted to identify all epi-
emiological, toxicological, and mechanistic studies relevant to
ardiac defects associated with developmental exposure to TCE
r its metabolites (TCA and DCA) that were published subsequent
o the ﬁnal systematic literature search conducted by EPA during
ompletion of the 2011 IRIS assessment [87]. A date-delineated
earch of PubMed, Toxline, and Web  of Science (WoS) was  con-
ucted (January 2010–January 2015), using search terms designed
o identify any publications that addressed TCE or its speciﬁed
etabolites. The search identiﬁed a total of 1769 unique citations,
hich were then screened using information contained in the title,
bstract, and/or full text. Citations excluded from further consider-
tion included studies that did not include an assessment of TCE or
ts metabolites, studies that did not directly assess or were not per-
inent to the evaluation of cardiac development, and publications
hat did not include primary research data (e.g., reviews, press arti-
les, meeting abstracts). The literature search did not identify any
ew experimental animal toxicology studies of fetal cardiac defects,
ut did identify two new epidemiological studies that assessed the
ssociation of TCE or chlorinated solvent exposures with cardiac
efects [71,29] and two new studies that provided mechanistic
nformation relevant to alterations of cardiac development follow-
ng TCE (or metabolite) exposures [58,66].
.2. Study quality review
For each epidemiological and toxicological study in the develop-
ental toxicity database for TCE, whether previously included in
he EPA TCE assessment [87] or newly identiﬁed in the updated
iterature search, a formal detailed review of study quality was
onducted.
Epidemiological data: Study quality evaluation criteria and a
general format for capturing epidemiological study data and
characterization have previously been developed by the IRIS pro-
gram and are summarized in the Guidelines for Developmental
Toxicity Risk Assessment [85]. These factors include study power,
potential bias in data collection, selection bias, measurement
biases associated with exposure and outcome, and consideration
of potential confounding and effect modiﬁcation. This format was
used to summarize study information and observed strengths,
biases, and confounding factors for each study. An independent
review of the study quality conclusions presented here was con-
ducted by a working group that included eight EPA experts in the
ﬁeld of epidemiology.
Animal toxicology data: Study quality evaluation criteria for in
vivo, in vitro, and avian in ovo developmental toxicology stud-
ies were developed speciﬁcally for this effort. These criteria
included considerations described in U.S. EPA [85] and focused
on the adequacy of study design and documentation of infor-
mation on the test subjects (e.g., species, strain, source, sex,
age/lifestage/embryonic stage), environment (e.g., husbandry,
culture medium), test substance (e.g., identiﬁcation, purity,
analytical conﬁrmation of stability and concentration), treat-
ment (e.g., dose levels, controls, vehicle, group sizes, duration,
route of administration), endpoints evaluated (e.g., schedule of
evaluation, randomization and blinding procedures, assessmenticology 65 (2016) 321–358 323
methods), and reporting (quality and completeness). Two  sep-
arate reviewers conducted independent assessments of each
in vivo mammalian study, and seven toxicologists independently
evaluated study quality for four mammalian in vivo studies that
had performed a detailed evaluation of developmental cardiac
defects [15,51,28,20].
2.3. Characterization of hazard and dose-response information
• Hazard: Critical elements of the identiﬁed epidemiological and
toxicological studies were extracted and summarized in tabular
format. For epidemiological studies, the exposure measure and
range, outcome classiﬁcation, participant selection and compa-
rability, consideration of likely confounding, data presentation
and analysis, and sample size were summarized. For animal
toxicology studies, the summary included information on the
test subjects (species, strain, sex, number of animals assigned
per group), exposure levels, timing, and duration, no-observed-
adverse-effect levels (NOAELs), lowest-observed-adverse-effect
levels (LOAELs), and treatment-related effects.
• Dose-response analysis: The cardiac malformation data [51]
were reanalyzed using the Benchmark Dose Software (BMDS)
nested logistic model that was  used in the EPA TCE assessment
[87] as well as other BMDS models to evaluate uncertainty related
to model selection and modeling assumptions [88]. A benchmark
response (BMR) of 0.01 (1%) extra risk was used, justiﬁed by the
severity of the effect.
2.4. Mechanistic data on developmental pathways and processes
The 2011 IRIS assessment noted that many of the cardiac
defects observed in humans and laboratory species (primarily rats
and chickens) involved septal and valvular structures. To further
characterize the potential for alterations in cardiac development,
studies that evaluated aspects of valvulo-septal defects identi-
ﬁed in the literature search, as well as mechanistic studies that
had been included in the 2011 IRIS TCE assessment, were exam-
ined for relevant information. The search and data evaluation
pointed to alterations in endocardial cushion formation and devel-
opment. This prompted a search of the Mouse Genome Informatics
(MGI) database (http://www.informatics.jax.org/) for genes associ-
ated with “abnormal cardiac epithelial to mesenchymal transition”
[MP:0008825]. As a consequence, newer mechanistic concepts
were explored.
2.5. Weight-of-evidence (WOE) evaluation
The WOE  (evidence integration) for fetal cardiac defects was
characterized according to the criteria described in the Frame-
work for Assessing Health Risk of Environmental Exposures to
Children [86], a scheme that was  adapted from principles of
causality assessment developed by [43]. Fig. 1 illustrates the
components (key factors) included in the WOE  analysis. Each
participant in the review independently assessed the WOE, and
through discussions arrived at a group consensus of the evi-
dence supporting stronger and weaker weights of association
for each key factor.
3. Results
3.1. Hazard for developmental cardiac defects3.1.1. Epidemiological data
The epidemiological studies were reviewed for associations
between maternal exposure to TCE and cardiac defects. Seven
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Table 1
Study Summary and Quality Assessment for Epidemiologic Studies on TCE Exposure and Congenital Malformations.
Reference Exposure Measure and
Range
Outcome Classiﬁcation Participant Selection
and Comparability
Consideration of Likely
Confounding
Data Presentation and
Statistical Analysis
Adequate Sample Size Additional Comments
Ruckart et al. [71] Individual level. Fate
and transport, and
water distribution
modeling, TCE, up to
1400 ppb; other
contaminates included
vinyl chloride,
1,2-dichloroethylene,
PCE, benzene. Average
monthly concentration
two months before and
after conception.
Self-reported, veriﬁed
by medical record;
NTD, oral clefts
prevalence,
conotruncal heart
defectsa.
United States.
n = 12,598 live births
among mothers
residing at Camp
Lejeune during
pregnancy, identiﬁed
from birth certiﬁcates
and media
campaign/referral,
1968 – 1985. Referents
selected from children
without a birth defect
(∼1:10 ratio),
unmatched to cases.
Excluded 54 cases due
to  lack of medical
veriﬁcation, refusal to
provide medical
records, and veriﬁed
not to have the
reported condition; 22
controls ineligible.
Bivariate analyses
adjusted for mother’s
age, previous
pregnancy, child’s sex,
child’s sibling with a
birth defect, father’s
occupational exposure
to  solvents, previous
pregnancy, alcohol use,
mother’s employment
status, use of prenatal
vitamins, or maternal
fevers.
Odds ratio and 95%
conﬁdence interval;
unconditional logistic
regression.
106 cases of NTDs, oral
clefts and
leukemia/non-Hodgkin
lymphoma;
medically-veriﬁed: 35
NTDs, 42 oral clefts;
TCE exposed, 8 NTDs, 9
oral clefts.
Odds ratio not reported
for conotruncal heart
defects. Less than 3
conotruncal heart
malformations
observed.
Forand  et al. [29] Area level. Maternal
residence in one of two
contaminated areas at
time of birth. Sample of
25% residences affected
by soil vapor intrusion:
Area 1, indoor air TCE,
range−0.18–140
ug/m3, median 16
ug/m3; Area 2, indoor
PCE, range 0.1 – 24
ug/m3.
Congenital
malformationsb,
including cardiac
(ICD−9 745.0–747.9c),
in <2 year old children,
NYSDOH Congenital
Malformations
Registry.
United States. n = 1440
live singleton births
(1090 in TCE area, 350
in  PCE area); referents,
1983–2000; 3.6 million
births in New York
State, excluding New
York City.
Adjusted for mother’s
age, education, race,
infant’s sex, number of
previous live births,
and adequate prenatal
care.
Rate ratios and 95%
conﬁdence intervals,
Poisson regression.
61 children (44 in TCE
area, 17 in PCE area)
with at least one
reportable birth defect.
TCE area, 25
surveillance defects, 15
cardiac malformations
(6 major, 3
conotruncal).
No births with NTDs or
oral clefts.
Yauck  et al. [94] Area level. Maternal
residence within 1.32
miles from at least one
TCE emissions source
at time of birth.
Cardiac malformations,
excluding patent
ductus arteriosus,
persistent foramen
ovale, or peripheral
pulmonary stenosis,
hospital medical
record, Milwaukee
Children’s Hospital.
United States. n = 4025
infants, born
1997–1999; cases from
hospital or birth
records, population
referents from birth
certiﬁcates frequency
matched by birth year;
excluded infants
≤23weeks, if 24–26
weeks, died within
48 h of birth, or Down’s
syndrome diagnosis;
one birth selected from
multiple births.
Dichotomized by age
(<38 years, ≥38 years);
no differences found
for race, ethnicity,
maternal education,
parity, number of
prenatal visits, or
cigarette use.
Odds ratio, logistic
regression.
245 cases and 3780
controls; TCE exposed,
46 cases, 715 controls.
Pre-existing diabetes,
chronic hypertension,
and alcohol associated
with outcome and not
included in TCE
statistical model.
The poorly-deﬁned
exposure surrogate and
lack of TCE exposure
monitoring makes
interpretation of
results difﬁcult.
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Bove et al. [9]; Bove [8] Area level. Maternal
1st trimester exposure
to TCE, municipal
water supply, 75 towns
(55 ppb, maximum
monthly estimate; 5%
of study population
above MCL  of 5 ppb),
other TTHMs.
Congenital
malformationsd,
including NTD, oral
clefts and cardiac
defects (ICD−9 745.0,
745.1, 745.2, 746.1,
746.3, 746.4, 746.7,
747.1, 747.3), NJDOH
Birth Defects Registry
and New Jersey fetal
death certiﬁcates.
United States.
n = 80,938 singleton
live-born infants and
594 singleton fetal
deaths, New Jersey
birth and death
records, 1985–1988.
Odds ratio adjusted if
differed from
unadjusted by ±15%
for maternal age, race,
education, parity
prenatal care, previous
stillbirth or
miscarriage, and child’s
sex.
Odds ratio, logistic
regression.
58 NTDs, 83 oral cleft,
108 major cardiac
defects; TCE >10 ppb, 4
NTDs, 9 oral cleft
defects, major cardiac
defects, including
ventricular septal
defects, NR.
Effect measure
estimates from
univariate analysis did
not differ by ±15% from
multivariate analyses.
Goldberg  et al. [35] Family member
exposed to municipal
well water
contaminated with TCE
(range: 6–239 ppb),
DCA, chromium.
Cardiac defects,
medically diagnosed
closest to birth date,
excluding syndromes
associated with cardiac
abnormalities,
supraventricular
tachycardia or isolated
ectopic cardiac beats
without gross anatomic
cardiac lesions, patent
ductus arteriosus in
premature infants,
peripheral pulmonary
stenosis and bicuspid
aortic value without
stenosis or
regurgitation.
United States. n = 1363
live births, conceived
between 1969 and
1987 whose parents
live in Tucson Valley
for 1 month before and
during 1st trimester of
pregnancy, identiﬁed
from cardiologist’s
records, 218 lacking 1st
trimester addresses,
406 disqualiﬁed, 31 not
residing in Tucson
during 1st trimester.
Additional control
groups: Groups 1 and 2
were current residents,
selected using RDD in
(a) proportion to all
telephone numbers or
(b) proportion to
population with
cardiac defects,
Compared to
non-contaminated
water area controls,
more cases were
Hispanic, case parents
were less educated and
were more likely
blue-collar, and fathers
were younger. No
adjustment for
potential confounders;
possible bias
introduced if
differential selection
between residents in
contaminated area and
rest of Tucson to
cardiologist.
Prevalence rates, odds
ratio.
707 families (246
exposed, 461
unexposed).
Population at risk not
fully elucidated
because did not include
cases living in study
area who were treated
at hospitals outside
Tucson area or subjects
who moved during the
study period. NR if
interviewers were
blinded. Use of family
as a control group
provides estimate of
the proportion of
households that had at
one member who
worked or resided in
the contaminated are,
not estimate of
exposure prevalence in
the birth population.
Lagakos  et al. [56] Maternal exposure
during full period of
pregnancy to 32
V0Cs detected in 1979
in two drinking water
wells, including TCE:
267 g/L,
tetrachloro-ethylene:
21 g/L, and
chloroform: 12 g/L.
Self-reported
congenital
malformationse,
including heart defects
(ICD–9 425.3, 745.2,
745.4, 745.9, 746.6,
476.9, 747.1, 747.2,
785.2), 1960–1982.
United States. n = 6219
residences with
telephones in Woburn,
Massachusetts, 1149
refused interview and
60 non-English
speaking; 4396
self-reported
pregnancies.
Depending on
outcome, adjusted for
infant sex, maternal
smoking during
pregnancy, year
pregnancy ended,
maternal age, prior
peri–natal death, prior
low birth weight,
and/or prior
musculoskeletal
anomaly.
Odds ratio, Cox
proportional hazard.
3.467 pregnancies with
infant living >7 days,
177 congenital
anomalies, 5
pregnancies with
mother receiving water
from contaminated
wells.
Self-reporting of
outcomes, potential
recall bias, and lack of
exposure data for
susceptible periods
during pregnancy
makes interpretation
of results difﬁcult.
Gm = grams; HCl = hydrochloric acid; IQ = interquartile; JEM = job-exposure-matrix; NR = not reported; NYSDOH = New York State Department of Health; RDD = random digit dialing; PCE = tetrachloroethylene; SES = socioeconomic
status;  TTHM = total trihalomethanes; VOC = voltile organic compounds.
aRuckert et al. [71] also studied childhood leukemia and non-Hodgkin lymphoma.
b Forand et al. [29] also studied term low birthweight, pre–term birth, and fetal growth restriction.
c Infants with patent ductus arteriosus (ICD-9 747.0) included if birthweight ≥2500 gm.
d Bove et al. [9] and Bove [8] also studied low (<2500 gm)  and very low birthweight (<1500 gm), small for gestational age, premature births examined but results not reported.
e Lagakos et al. [56] also studied perinatal death, low birth weight, and childhood disorders but did not report results.
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Table 2
Consideration of Biases, Confounding, and Chance in TCE – Cardiac Defect Epidemiology Studies.
Reference Selection bias Information bias,
Exposure
Information bias,
Outcome
Recall bias Chance Confounding
Forand et al. [29]
Cohort
Unlikely Likely, area–level
exposure assignment
but soil vapor intrusion
found throughout the
TCE study area
Unlikely, birth defects
registry study with
medically-veriﬁed
outcomes
Unlikely No Unlikely, adjusted for
important maternal
risk factors, including
prenatal care but not
folic acid intake
Yauck  et al. [94]
Case-control
Unlikely Likely, area-level
exposure assignment;
poorly deﬁned
exposure surrogate
Unlikely, birth
certiﬁcate and birth
defects registry study
Unlikely No Likely, univariate
statistical analyses not
adjusted for maternal
risk factors
Bove  et al. [9]; Bove [8]
Cohort
Unlikely Likely, area–level
exposure assignment
Unlikely, registry
(birth, congenital
malformation) study
Unlikely Yes Unlikely, univariate
statistical analysis;
effect estimate from
multivariate analysis
adjusted for important
maternal risk factors,
but not folic acid
intake, not different by
±15% from univariate
Goldberg et al. [35]
Prevalence
Likely. Two  of three
control groups are
inappropriate and
sparse details on
selection of 3rd control
group
Likely, area-level
exposure assignment
Unlikely, cases
identiﬁed from
cardiologists ﬁles
Likely No Unable to assess; study
lacks details of
statistical analysis
Lagakos  et al. [56]
Prevalence
Unlikely Likely, area-level
exposure assessment
Likely, self-reported
outcomes
Likely Yes Unlikely, age,
education, race,
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teports from six epidemiological studies that investigated devel-
pmental cardiac birth defects in relation to estimated TCE
xposure during pregnancy were identiﬁed in the literature
71,29,94,8,9,35,56]; ﬁve of the seven reports were reviewed in
he EPA’s 2011 Trichloroethylene Toxicological Review [87]. The
ublication by Forand et al. [29] analyzed the same study popu-
ation described in the ATSDR [3,2] reports referenced in U.S. EPA
87]. Bove [8] and Bove et al. [9] report twice on the same study
ubjects. All of the studies examined outcomes in relation to oral
xposures with the exception of the inhalation exposure studies
rom Forand et al. [29] and Yauck et al. [94]. The epidemiological
tudy summaries and quality assessments are presented in Table 1.
onsideration of bias, confounding, and chance are summarized in
able 2.
The studies were of different populations, living in different
tates, and of different epidemiological designs. Forand et al. [29]
s a retrospective cohort study of 1440 live births among New York
esidents in an area contaminated with TCE via vapor intrusion.
ove [8]/Bove et al. [9] is a cross-sectional study of 80,938 singleton
ive-born infants and 594 singleton fetal deaths among residents in
orthern New Jersey receiving TCE in municipal water supplies.
 strength of both studies is the use of state records, including
tate Birth Defects Registries with clinically veriﬁed outcomes that
educe information and subject recall bias, and the ability to con-
rol for potential confounding factors. Both of the studies observed
n elevated relative risk estimate for major cardiac defects: a rela-
ive risk of 1.24 (a 50% conﬁdence interval (CI) was reported: 0.75,
.94) for >10 ppb TCE in municipal drinking water supplies com-
ared to TCE exposure ≤1 ppb in Bove [8]/Bove et al. [9]; and an
stimated relative risk of 2.40 (95% CI: 1.00, 5.77) compared to the
est of New York State, excluding New York City in Forand et al.
29]. Both studies report relative risk estimates for speciﬁc defects:
.30 (50% CI: 0.88, 1.87) for ventricular septal defects and exposure
o >5 ppb TCE in drinking water compared to <1 ppb (Bove [8]/Bove
t al. [9]) and 4.91 (95% CI: 1.58, 15.24) for conotruncal defect in
he TCE-contaminated area compared to the rest of New York State,prenatal care, and
parity evaluated as
potential confounders
excluding New York City [29]. Yauck et al. [94], a case-control study
of 245 cases and 3780 controls, reported that living within 1.32
miles from at least one TCE emissions source in Wisconsin had a
strong relative risk estimate of 6.2 (95% CI: 2.6, 14.5) for cardiac
defects in infants born to mothers aged 38 years or older after con-
trolling for potential confounding, but no association for cardiac
defects was  observed among infants of mothers aged less than 38
years (RR = 0.9, 95% CI: 0.6, 1.2). The original case-control study by
Goldberg et al. [35] reported that the likelihood of family exposure
to the contaminated water area among families with cardiac defects
was three times that of exposure among randomly selected families
in the same general locality. In a review article that included the
Goldberg et al. [35] study, Bove et al. [7] calculated an unadjusted
prevalence ratio of cardiac defects among residents of the contam-
inated area with ﬁrst-trimester exposure compared with residents
in uncontaminated areas of 2.58 (95% CI: 2.0, 3.4). Ruckart et al. [71]
reported little detail on cardiac defects in a population exposed to
TCE-contaminated water but noted a lower than expected num-
ber of conotruncal heart defects−although neither precise counts
nor conﬁdence intervals were reported, and the authors did not
draw any conclusions concerning TCE exposure and the occurrence
of all cardiac defects or conotruncal heart defects. Lagakos et al.
[56] reported no association (p = 0.91) between exposure to TCE-
contaminated water in Woburn, Massachusetts and a much larger
categorical grouping of ‘cardiovascular anomalies’ which included
heart murmurs (15 of 43 anomalies) and only 2 conotruncal heart
defects.
Forand et al. [29] and Bove [8]/Bove et al. [9] provide evidence for
an association between maternal TCE exposure and cardiac defects.
A more mixed pattern of results is seen in three other studies with
greater potential for bias and confounding [94,35,56]; however,
the results of these studies are not necessarily inconsistent with
the association observed by Forand et al. [29] or Bove [8]/Bove
et al. [9] because, for the database as a whole, the epidemiolog-
ical studies are imprecise in estimating effects due to the small
number of cardiac defects. Additionally, information bias related
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Fig. 1. Conceptual view of a Weight-of-Evidence evaluation. Considerations within
a  WOE  evaluation of toxicity data are shown. The relative weight of each considera-
tion can vary, based upon the data [86], Fig. 4-4). Temporality is the premise that the
exposure must occur prior to the outcome. Strength of association is the considera-
tion of study rigor and statistical power. Variability analysis considers the source of
variability within individual studies. Uncertainty analysis considers information or
data gaps in individual studies and in the comprehensive database of information.
Qualitative dose-response relationship is the change in an effect, and the degree of
the change, as a function of exposure or dose. Experimental evidence is the alter-
ations in response or rate of response resulting from manipulation of exposure.
Reproducibility is the observation of speciﬁc effects under varied conditions. Bio-
logical plausibility is the determination of whether an observed outcome could be
attributed to the toxicological insult, given the currently known science. Alternative
or  multiple explanations are other explanations for the observed outcome(s) follow-
ing  the exposure of interest. Speciﬁcity refers to determination of the relationship
between one exposure, the effect(s), and whether each effect is mediated through a
single or alternative MOAs. Coherence is the extent to which the data are similar in
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ity study design [15,42,39,21,74]. The studies by Hardin et al. [39]utcome and exposure/dose and whether they support each biologically plausible
ypothesis or MOA.
o the exposure assessment in these studies may  provide alterna-
ive explanations for the apparent heterogeneity. As the exposure
ssessment methods in these studies are at an aggregate level based
n locality (rather than based on individual-level measurements),
ne can assume that the incumbent exposure measurement error
also known as information bias) is non-differential with respect
o cardiac defects. That is, any errors in exposure assessment are
xpected to be independent of case status. Such non-differential
isclassiﬁcation of exposure would typically result in bias towards
he null [70] and limit the ability of the studies to detect some asso-
iations and possibly exposure-response relationships. None of the
tudies considered maternal folic acid intake, which may  reduce
he risk of cardiac defects [45] and is thus a potential confounder.
ecause TCE has been shown to induce folate deﬁciency in rats [22]
nd in workers [36], folate concentrations may  be on the direct
ausal pathway from TCE exposure to cardiac defects. Thus it was
ethodologically appropriate for these studies not to control for
olic acid/folate as that would have induced bias towards the null.
ather, women with low dietary intake of folic acid may  represent
 susceptible sub-group. Both Forand et al. [29] and Bove [8]/Bove
t al. [9] adjust for other maternal risk factors, including adequate
renatal care, as potential confounding factors. Observations in the
ther studies are more uncertain compared to Forand et al. [29] and
ove [8]/Bove et al. [9], and the observed heterogeneity of results
ay  be due to alternative explanations, such as bias, chance, or
otential confounding. Use of hospital cases by Yauck et al. [94]
nd cases identiﬁed from cardiologists’ records by Goldberg et al.
35] may  introduce possible selection bias. It is difﬁcult to evalu-
te control for potential confounding in Goldberg et al. [35] due to
imited reporting in the publication. The self-reporting of outcome
n Lagakos et al. [56] introduces uncertainty because of potential
elective reporting.icology 65 (2016) 321–358 327
In summary, epidemiologic data provide some support for the
possible relationship between maternal TCE exposure and car-
diac birth defects. Forand et al. [29] provide clear evidence of an
association between living in an area contaminated by TCE via
vapor intrusion and increased risk of conotruncal heart defects,
and Bove [8]/Bove et al. [9] provide limited evidence for an asso-
ciation between maternal exposure to TCE, or the combination of
TCE and other chlorinated solvents in drinking water, and cardiac
defects. However, there are uncertainties in the interpretation of
the epidemiological data on Bove [8]/Bove et al. [9] because of the
small number of observed TCE-exposed cardiac defect cases, sparse
reporting on TCE exposure and congenital heart defects (CHDs) in
both publications, and the study’s cross-sectional design that could
not establish temporality. Two  other studies with potential biases
also observed elevated risk estimates between TCE exposure and
cardiac defects [94,35] and these provide some corroboration of the
observations in Forand et al. [29]. The lack of supporting evidence
from Ruckart et al. [71] may  be a consequence of the small number
of reported cases. Additionally, because Lagakos et al. [56] exam-
ined a much more broadly deﬁned set of outcomes, their ﬁndings
are likely much less speciﬁc than conotruncal heart defects or even
cardiac defects as reported by the other investigators.
The limited ﬁnding of an association between TCE exposure
and conotruncal heart defects, in particular, and cardiac defects
more generally has coherence with the broader epidemiological
literature that reports association between maternal occupational
exposure to degreasing solvents or to organic solvents and CHDs
[11,34,93,83,84]. Although the reported associations between TCE
exposure and increased risks of cardiac defects were observed in
several studies [29,94,8,9,35], overall, these epidemiologic studies
are not sufﬁcient to establish a causal link between TCE exposure
and cardiac defects in humans. This conclusion is consistent with
other reviews of the epidemiological literature for TCE exposures
and CHD [13,90,38]. Additional research could better characterize
human exposures and health outcomes.
3.1.2. Toxicological data
The experimental toxicology database for the assessment
of developmental cardiac defects resulting from TCE exposure
includes in ovo chicken studies, in vitro assays, and rodent stud-
ies that assessed fetal morphology following in utero exposures
to TCE or its oxidative metabolites. Summaries of studies that
assessed cardiac development in mammalian laboratory animal
models are presented in Table 3a (inhalation exposure to TCE),
Table 3b (oral exposures to TCE), and Table 3c (oral exposures to
DCA and TCA). Studies using non-mammalian or in vitro test sys-
tems to assess cardiac development following exposures to TCE,
DCA, or TCA are summarized in Table 3d. Study strengths and lim-
itations for the mammalian inhalation and oral studies of TCE or
its metabolites (DCA or TCA) are summarized in Table 4. Exposure-
response arrays for general categories of adverse developmental
outcomes (decreased survival, decreased growth, and altered mor-
phological development, including cardiac defects) are presented
in Figs. 2–4 for studies with gestational inhalation exposures to TCE,
oral exposures to TCE, and oral exposures to DCA and TCA (respec-
tively). Incidence data for speciﬁc developmental ﬁndings are not
presented herein since that information is summarized in the IRIS
assessment [87].
3.1.2.1. Inhalation rodent and rabbit TCE studies. Five publications
reported the conduct of studies in which TCE was administered by
inhalation exposure to rats, using a prenatal developmental toxic-also included rabbits exposed to TCE, and the study by Schwetz
et al. [74] also included mice exposed to TCE. None of these stud-
ies reported cardiac defects in fetuses following in utero exposures
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Table 3a
Summary of mammalian in vivo toxicity studies assessing cardiac development — inhalation exposures.
Reference Species/strain/
sex/number
Exposure level/
Durationa
NOAEL; LOAELb Effects
Carney et al. [15] Rat, Sprague-Dawley, females,
27 dams/group
0, 50, 150, or 600 ppm
(600 ppm = 3.2 mg/L)c
(268.5, 805.5, 3222 mg/m3)
6  h/d;
GDs 6–20
Maternal NOAEL: 150 ppm
(805.5 mg/m3)
Maternal LOAEL: 600 ppm
(3222 mg/m3)
↓ Body weight gain (22% less
than control) on GDs 6–9 at
600 ppm.
Developmental NOAEL:
600 ppm (3222 mg/m3)
No evidence of developmental
toxicity, including heart
defects.
Dorfmueller et al. [21] Rat, Long-Evans, females, 30
dams/group
0 or 1800 ± 200 ppm
(9674 ± 1075 mg/m3)c
2 wks, 6 h/d, 5 d/wk; prior to
mating and/or on GDs 0–20
Maternal NOAEL:
1800 ± 200 ppm
(9674 ± 1075 mg/m3)
No maternal abnormalities.
Developmental LOAEL:
1800 ± 200 ppm
(9674 ± 1075 mg/m3)
Statistically signiﬁcant ↑
skeletal and soft tissue
anomalies in fetuses from
dams exposed during
pregnancy only. No statistically
signiﬁcant treatment effects on
behavior of offspring 10, 20, or
100 d postpartum. Body weight
gains statistically signiﬁcant ↓
in pups from dams with
pre-gestational exposure.
Hardin et al. [39] Rat, Sprague-Dawley, female,
nominal 30/group
0 or 500 ppm
(0 or 2685 mg/m3)
6–7 h/d;
GDs 1–19
Maternal NOAEL: 500 ppm
(2685 mg/m3)
No maternal toxicity.
Developmental NOAEL:
500 ppm (2685 mg/m3)
No embryonic or fetal toxicity.
Rabbit, New Zealand white,
female, nominal 20/group
0 or 500 ppm
(0 or 2685 mg/m3)
6–7 h/d;
GDs 1–24
Maternal NOAEL: 500 ppm
(2685 mg/m3)
No maternal toxicity.
Developmental LOAEL:
500 ppm (2685 mg/m3)
Hydrocephaly observed in two
fetuses of two litters,
considered equivocal evidence
of teratogenic potential.
Healy  et al. [42] Rat, Wistar, females, 31–32
dams/group
0 or 100 ppm
(0 or 535 mg/m3)
4 h/d;
GDs 8–21
Maternal NOAEL: 100 ppm
(535 mg/m3)
No maternal abnormalities.
Developmental LOAEL:
100 ppm (535 mg/m3)
Litters with total resorptions
statistically signiﬁcant ↑.
Statistically signiﬁcant ↓ fetal
weight, and ↑ bipartite or
absent skeletal ossiﬁcation
centers.
Schwetz et al. [74] Rat, Sprague-Dawley, female,
20–35/group
Mouse, Swiss-Webster,
females, 30–40 dams/group
0 or 300 ppm
(0 or 1611 mg/m3)
7 h/d;
GDs 6–15
Maternal LOAEL: 300 ppm
(1611 mg/m3)
4–5% ↓ maternal body weight
Developmental NOAEL:
300 ppm (1611 mg/m3)
No embryonic or fetal toxicity;
not teratogenic.
Developmental LOAEL:
150 ppm (805.5 mg/m3)
Speciﬁc gravity of brains
statistically signiﬁcant ↓ at
PNDs 0, 10, and 20–22. Similar
effects at PNDs 20–22 in
occipital cortex and
cerebellum. No effects at 1 mo
of age.
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da To convert concentrations in air (at 25 ◦C) from ppm to mg/m3: mg/m3 =
000  mg/m3 = 1 mg/L (air). Source: U.S. EPA, Technology Transfer Network – Air Tox
b NOAEL and LOAEL are based upon reported study ﬁndings.
o TCE; however, of these, only the Carney et al. [15] and Schwetz
t al. [74] provided sufﬁcient study detail to demonstrate that they
ere conducted in accordance with good laboratory practices and
xamined the fetuses using speciﬁc methods designed to detect
bnormalities of cardiac development.
.1.2.2. Oral rodent TCE studies. Six studies reported the results of
ral administration of TCE to rodents during fetal development
51,28,61,62,20,18]. All studies were performed in rats, except
osby and Dukelow [18] which used mice. In all of these rodent
tudies, TCE was administered by gavage, with the exception of the
awson et al. [20] and Johnson et al. [51] studies, in which TCE was
dministered via drinking water. Only the two drinking water stud-
es detected statistically signiﬁcant treatment-related fetal cardiac
efects.) × (molecular weight of the compound)/(24.45). For TCE: 1 ppm = 5.37 mg/m3.
b  Site, http://www.epa.gov/ttnatw01/hlthef/tri-ethy.html, last accessed 08-06-15.
The gavage studies by Fisher et al. [28], Narotsky et al. [62], and
Narotsky and Kavlock [61] were conducted in accordance with good
laboratory procedures. While Fisher et al. [28] conducted their car-
diac evaluations with the same methods as described in Johnson
et al. [51], and the ﬁrst author of the Johnson et al. [51] paper par-
ticipated as a member of the cardiac dissection team for the Fisher
et al. [28] study, TCE-related cardiac defects were not detected.
The studies by Narotsky et al. [62] and Narotsky and Kavlock [61]
evaluated neonatal growth and viability, and examined cardiac and
other soft tissue morphology only in pups that had died; no cardiac
defects were reported. The study by Cosby and Dukelow [18] did
not conduct a detailed assessment of cardiac development.3.1.2.3. Oral rodent metabolite studies. Detailed information on the
toxicokinetics of TCE is presented in the IRIS TCE assessment
[87,Chap. 3]. Data in humans and rodents indicate that TCE crosses
S.L.
 M
akris
 et
 al.
 /
 R
eproductive
 Toxicology
 65
 (2016)
 321–358
 
329
Table 3b
Summary of mammalian in vivo toxicity studies assessing cardiac development—oral exposures.
Reference Species/strain/
sex/number
Dose level/exposure
durationa
Route/vehicle NOAEL; LOAELb Effects
Cosby and Dukelow [18] Mouse, B6D2F1, female,
28–62 dams/group
0, 24, or 240 mg/kg-d
GDs 1–5, 6–10, or 11–15
Gavage in corn oil Maternal NOAEL: 240 mg/kg-d No maternal toxicity.
Developmental NOAEL: 240
mg/kg-d
No effects on embryonic or fetal
development.
Dawson et al. [20] Rat, Sprague-Dawley, 116
females allocated to 11
groups
0, 1.5, or 1100 ppm (mg/L)
(0, 0.18 or 133 mg/kg-d)
2 mo before mating and/or
during gestation
Drinking water Maternal NOAEL: 1100 ppm
(132 mg/kg-d)
No maternal toxicity.
Developmental LOAEL:
1.5 ppm (0.18 mg/kg-d)
Statistically signiﬁcant ↑ in heart
defects, primarily atrial septal defects,
found at both dose levels in groups
exposed prior to pregnancy and during
pregnancy, as well as in group exposed
to  1100 ppm dose during pregnancy
only. No statistically signiﬁcant ↑ in
congenital heart defects in groups
exposed prior to pregnancy only.
Fisher  et al. [28] Rat, Sprague-Dawley,
female, 20–25 dams/group
0 or 500 mg/kg-d
GDs 6–15
Gavage in soybean oil Maternal NOAEL: 500 mg/kg-d No maternal toxicity.
Developmental NOAEL: 500
mg/kg-d
No developmental toxicity. The
incidence of heart malformations for
fetuses from TCE-treated dams (3–5%)
did not differ from negative controls.
No eye defects observed.
Johnson  et al. [51] Rat, Sprague-Dawley,
female, 9–13/group, 55 in
control group
0, 2.5, 250, 1.5, or
1100 ppm
(0, 0.00045, 0.048, 0.218, or
129 mg/kg-d)d
GDs 0–22
Drinking water Developmental NOAEL: 2.5 ppb
(0.00045 mg/kg-d)
Developmental LOAEL:
250 ppbb (0.048 mg/kg-d)
Statistically signiﬁcant ↑ in percentage
of abnormal hearts and the percentage
of litters with abnormal hearts at
≥250 ppb.
Narotsky  et al. [62] Rat, F344, females, 8–12
dams/group
0, 10.1, 32, 101, 320, 475,
633, 844, or 1125 mg/kg-d
GDs 6–15
Gavage in corn oil Maternal LOAEL: 475 mg/kg-d Statistically signiﬁcant dose-related ↓
dam body weight gain at all dose levels
on GDs 6–8 and 6–20. Delayed
parturition at ≥475 mg/kg-d; ataxia at
≥633 mg/kg-d; mortality at
1125 mg/kg-d.
Developmental NOAEL:
32 mg/kg-d
Developmental LOAEL:
101 mg/kg-d
↑ full litter resorption and postnatal
mortality at ≥425 mg/kg-d.
Statistically signiﬁcant prenatal loss at
1125 mg/kg-d. Pup body weight ↓ (not
statistically signiﬁcant) on PNDs 1 and
6. Statistically signiﬁcant ↑ in pups
with eye defects at 1125 mg/kg-d.
Dose-related (not statistically
signiﬁcant) ↑ in pups with eye defects
at  ≥101 mg/kg-d.
Narotsky and Kavlock [61] Rat, F344, females, 16–21
dams/group
0, 1125, or 1500 mg/kg-d
GDs 6–19
Gavage in corn oil Maternal LOAEL: 1125 mg/kg-d Ataxia, ↓ activity, piloerection;
dose-related ↓ body weight gain.
Developmental LOAEL:
1125 mg/kg-d
Statistically signiﬁcant ↑ full litter
resorptions, ↓ live pups/litter;
statistically signiﬁcant ↓ pup body
weight on PND 1; statistically
signiﬁcant ↑ incidences of
microophthalmia and anophthalmia.
a For conversion of drinking water or dietary doses to mg/kg-d when no body weight or compound consumption data were available: mg/L in water x subacute conversion factor (0.121 for female rats, 0.191 for female mice);
mg/L  in water x subchronic conversion factor (0.093 for female rats, 0.164 for female mice); mg/kg (ppm) in feed x subacute conversion factor (0.117 for female rats, 0.224 for female mice); mg/kg (ppm) in feed x subchronic
conversion  factor (0.091 for female rats, 0.215 for female mice). For developmental studies, offspring duration of exposure was  used; subacute conversion factor was applied unless otherwise noted. Reference: EFSA [25].
b NOAEL and LOAEL are based upon reported study ﬁndings.
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Table 3c
DCA and TCA: Summary of mammalian in vivo toxicity studies assessing cardiac development—oral exposures.
Reference Species/strain/
sex/number
Dose level/
exposure duration
Route/vehicle NOAEL; LOAELa Effects
DCA
Smith et al. [79] Rat, Long Evans,
female, 19–21
dams/group
A: 0, 14, 140, or
400 mg/kg-d
B: 0, 900, 1400, 1900,
or 2400 mg/kg-d
GDs 6–15
Gavage in water Maternal LOAEL:
14 mg/kg-d
Increased adjusted liver weight
at ≥14 mg/kg-d; decreased
body weight gain at
≥140 mg/kg-d; increased
spleen and kidney weights at
≥400 mg/kg-d; mortality at
≥1400 mg/kg-day
Developmental LOAEL:
140 mg/kg-d
Increased soft tissue
malformations (primarily
cardiovascular, e.g., defects
between ascending aorta and
right ventricle) at
≥140 mg/kg-d; decreased fetal
weight and length at
≥400 mg/kg-d.; increased
resorptions and increased
orbital anomalies at
≥900 mg/kg-d
Fisher et al. [28] Rat, Sprague-Dawley,
female, 20 dams/group
0 or 300 mg/kg-d
GDs 6–15
Gavage in water Maternal LOAEL:
300 mg/kg-d
Decreased body weight gain
Developmental LOAEL:
300 mg/kg-d
Decreased fetal weight; no
signiﬁcant difference from
control in percent fetuses with
cardiovascular malformations;
no increased resorptions
Epstein  et al. [27] Rat, Long Evans,
female, 7–10
dams/group
0 or 1900 mg/kg-d
GDs 6–8, 9–11, or
12–15
0 or 2400 mg/kg-d
GDs 10, 11, 12, or 13
0 or 3500 mg/kg-d
GDs 9, 10, 11, 12, or 13
Gavage in water Maternal LOAEL: Not
characterized
Not reported
Developmental LOAEL:
1900 mg/kg-d
Increased interventricular
septal defects, membranous
type, and high interventricular
septal defects; fetal weight and
survival data not reported
TCA
Smith  et al. [78] Rat, Long Evans,
female, 20–26
dams/group
0, 330, 800, 1200, or
1800 mg/kg-d
GDs 6–15
Gavage in water Maternal LOAEL:
330 mg/kg-d
Increased spleen and kidney
weights; decreased body
weight gain at
≥800 mg/kg-day.
Developmental LOAEL:
330 mg/kg-d
Decreased fetal weight and
length; soft tissue
malformations (primarily
cardiovascular, e.g.,
interventricular septal defect
and levocardia, at incidences
ranging from 5.4–95% in
treated groups); increased
postimplantation loss at
≥800 mg/kg-d; skeletal
malformations, mainly orbital
anomalies, at 1200 and
1800 mg/kg-day.
Fisher et al. [28] Rat, Sprague-Dawley,
female, 19 dams/group
0 or 300 mg/kg-d
GDs 6–15
Gavage in water Maternal LOAEL:
300 mg/kg-d
Decreased body weight gain
Developmental LOAEL:
300 mg/kg-d
Decreased fetal weight; no
signiﬁcant difference from
control in percent fetuses with
cardiovascular malformations;
no increased resorptions
Johnson et al. [49] Rat, Long Evans,
female, 55 control, 11
TCA
0 or 2730 ppm
(291 mg/kg-d)
GDs 1–22
Drinking water Maternal LOAEL:
291 mg/kg-d
Decreased body weight gain
Developmental LOAEL:
291 mg/kg-d
Decreased fetal weight;
increased resorptions per
litter; increased percent
fetuses with abnormal hearts
t
r
d
h
da NOAEL and LOAEL are based upon reported study ﬁndings.
he placenta following maternal inhalation exposure. The major
oute of TCE biotransformation in humans and rodents is CYP-
ependent oxidative metabolism. Metabolic saturation occurs at
igh oral dose levels in rodents (>1000 mg/kg-day), at much higher
oses than those used in the Johnson et al. [51] study (i.e., rang-(10.5% vs 2.15% in controls)
ing from 0.048 to 129 mg/kg-day). Tissue distribution experiments
using various routes of administration produced time-course data
of TCE tissue concentrations that were used to develop a PBPK
model for all routes of exposure. Both the applied dose and the
PBPK-modeled internal dose-metrics of the oxidative metabolites
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Table 3d
Summary of non-mammalian and in vitro studies on TCE and metabolites (DCA and TCA) assessing cardiac development.
Reference Species/strain/
sex/number
Dose level/
exposure duration
Route/vehicle NOAEL; LOAELa Effects
Avian In Ovo
Bross et al. [12] Chicken, white leghorn,
20–24 embryos/group
TCE: 0, 1, 5, 10, or 25 mol/egg
Single injection on day 1 or 2
In ovo injection in
mineral oil
Developmental LOAEL:
1 mol
Decreased survival at ≥1 mol; increased edema, light
pigment, abnormal beak, club foot, and patchy feathers at
≥1 mol; evisceration at ≥5 mol; growth not affected;
visceral (including cardiac) development was not assessed
Drake  et al. [23] Chicken, white
leghorn, Babcock and
Bovan strains, 32–46
embryos/group
TCE: 0, 0.2, 4, or 200 nmol/egg (0,
3, 60, or 3000 nM/egg)
Single injections on HH13, HH15,
HH17, and HH20; assessed on
HH24 and HH30
In ovo injection in
saline
Developmental LOAEL:
4 nmol
Decreased survival on HH30, increased proliferative index
in  outﬂow tract (OFT) and atrioventricular canal (AVC)
cardiac cushion mesenchyme on HH24, increased mean
cushion cellularity, and decreased blood ﬂow on HH24 at
≥4 nmol;
TCA:  0 or 4 nmol/egg (0 or
60 nM/egg)
Injections on HH13, HH15, HH17,
and HH20; assessed on HH24 and
HH30
In ovo injection in
saline
Developmental LOAEL:
4 nmol
Decreased survival on HH30, increased proliferative index
in  OFT and AVC cardiac cushion mesenchyme on HH24,
increased mean cushion cellularity on HH24 at ≥4 nmol
Drake  et al. [24] Chicken, white leghorn,
Bovan strain, 35–117
embryos/group
TCE and TCA: 0, 0.2, 2, 4, 20, or
200 nmol/egg (0, 3, 30, 60, 300, or
3000 nM/egg)
Single injections on HH13, HH15,
HH17, and HH20; assessed on
HH18, HH21, and HH23
In ovo injection in
saline
Developmental NOAEL:
0.2 nmol
No alterations in cardiac development on HH18, HH21, or
HH23 were observed, since exposure was during period of
cardiac speciﬁcation rather than during period of
valvuloseptal morphogenesis as in Drake et al. [23]
Elovaara et al. [26] Chicken, white leghorn, SK
12 strain, 9–14
embryos/group
TCE: 0, 5, 25, 50, or 100 mol/egg
Single injection on day 2 or 6
In ovo injection in olive
oil
Developmental LOAEL:
5 mol
Increased malformations (exteriorization of viscera,
edema, eye abnormalities, and skeletal abnormalities) in
surviving 14- or 15-day embryos at ≥5 mol; decreased
survival, weight, and length at 100 mol; visceral
(including cardiac) development was not assessed
Loeber  et al. [57] Chicken, white leghorn,
strain not reported, 91–128
treated embryos/group;
266-7 control
embryos/group
TCE: 0, 5, 10, 15, 20, or 25 M/egg
Single injection on day 6, 12, 18, or
23; assessed at HH29, HH 34, or
HH44
In ovo injection in
saline or mineral oil
Developmental LOAEL:
10 M
Overall increased cardiac malformations and embryo
death in all treated embryos vs. control (categorized as
ectomesenchymal tissue migration abnormalities, ECM
abnormalities, and cell death abnormalities); increased
percent embryos with cardiac malformations at ≥10 M;
Rufer  et al. [72] Chicken, white leghorn,
Hyline strain W36, 35–117
embryos/group
TCE: 0, 0.2, 4, 40, 200, or 2000
nmol/egg (0, 0.4, 8, 80, 400, or
4000 ppb/egg)
Single injections on HH13, HH15,
HH17, HH20, or HH24; assessed on
HH24 and HH30
In ovo injection in
saline
Developmental LOAEL:
4 nmol
Decreased survival on HH30 following exposure on HH15
or HH17 at ≥4 nmol; increased incidence of muscular
ventricular septal defects (VSD) in embryos treated on HH
17 (related blood ﬂow abnormalities conﬁrmed by Doppler
imaging); increased abnormalities of cardiac structure and
function noted by echocardiography in HH28 treated
embryos (incidence data not provided).
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Table 3d (Continued)
Reference Species/strain/
sex/number
Dose level/
exposure duration
Route/vehicle NOAEL; LOAELa Effects
Zebra Fish
Hassoun et al. [41] Zebraﬁsh (Danio rerio), 30
embryos/group
DCA: 0, 4, 8, 16, or 32 mM
Exposed from 4 to 144 h
post-fertilization (hpf)
Petri dish: 20 mL
buffered water, with
60 mg  sea salt/L
Developmental LOAEL:
4 mM
Dose-related increased mortality at ≥8 nM on 8–55 hpf;
hatching delayed at 55 hpf in ≥8 mM;  increased yolk sac
edema at ≥8 nM;  increased craniofacial (jaw and mouth)
abnormalities at 80 hpf: 5% at 4 and 8 mM,  75% at ≥16 mM;
skeletal muscle deformation and notochord/muscular
lordosis at ≥16 mM by 144 hpf; abnormal feeding behavior
at  ≥4 mM by 144 hpf; increased heart rate at ≥16 mM at
32, 55, and 80 hpf and decreased heart rate with near
cessation of peripheral blood ﬂow at ≥16 mM at 144 hpf;
increased superoxide anion and nitric oxide production at
≥4  nM by 80 hpf
Williams et al. [91] Zebraﬁsh (Danio rerio), 30
embryos/group
DCA: 0 or 32 mM
(Ellagic acid groups were also
conducted but are not described
here)
Exposed from 4 to 144 h
post-fertilization (hpf)
Petri dish: 20 mL
buffered water
Developmental LOAEL:
32 mM
At 32 mM:  100% mortality after 144 hpf; hatching rate
delayed at 55 hpf; yolk sac and/or cardiac edema at
55–144 hpf; increased craniofacial (jaw and mouth)
abnormalities at 80 hpf; skeletal muscle deformation and
notochord/muscular lordosis by 144 hpf; abnormal feeding
behavior at 144 hpf; increased heart rate at 32 and 55 hpf
and decreased heart rate at 80 hpf with near cessation of
peripheral blood ﬂow at 144 hpf; increased superoxide
anion at 144 hpf and nitric oxide by 55 hpf
In  Vitro
Hunter et al. [44] Mouse, CD-1, 3–6 somites,
24 control and 10–18
treated embryos/group
DCA: 0,734, 1468, 4403, 4403,
5871, 7339, 11010, or 14680 M
24 h exposure
Whole embryo culture Developmental LOAEL:
5871 M
Increased % malformations and % neural tube defects,
decreased mean number of somites at ≥5871 M;
increased pharyngeal arch defects and heart defects at
≥7339 M; increased rotational defects, eye defects, and
somite dysmorphology at ≥11010 M
Mouse,  CD-1, 3–6 somites,
106 control and 10–56
treated embryos/group
TCA: 0, 500, 1000, 2000, 3000,
4000, or 5000 M
24 h exposure
Whole embryo culture Developmental LOAEL:
2000 M
Increased% malformations and% neural tube defects,
decreased mean number of somites at ≥2000 M;
increased eye defects and heart defects at ≥3000 M;
increased somite dysmorphology at 4000 M
Mishima  et al. [60] Chicken, white leghorn,
strain not reported,
HH13-14, 40–104
embryos/group
TCE: 0, 10, 40, or 80 ppm
24 h exposure
Whole embryo culture Developmental LOAEL:
80 ppm
Decreased mesenchymal cell number in superior and
inferior AV cushions at 80 ppm
Saillenfait et al. [73] Rat, Sprague-Dawley, GD
10 explants, 4–7 somites,
20 embryos/group
TCE: 0, 2.5, 5, 10, 15, or 30 mM
46 h exposure
Whole embryo culture Developmental LOAEL:
5 mM
Decreased yolk sac diameter, crown-rump length, head
length, and% malformed (brain defects and reduction in
embryonic axis) at ≥5 mM;  increased malformations: bend
in embryonic axis, reduction in ﬁrst brachial arch, otic
system defect, defective ﬂexion, absence of hindlimb bud,
delayed yolk sac circulation at ≥10 mM;  increased eye
defects and overall poor and abnormal development at
≥15 mM;  no cardiac defects noted.
a NOAEL and LOAEL are based upon reported study ﬁndings.
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Table 4
Study Quality Summary for Toxicology Studies that Assessed TCE Exposure and Developmental Effects.
Reference Exposure Quality Test Subjects Study Design Endpoints Data & Statistics Reporting
In Vivo Mammalian Inhalation Studies
Carney et al. [15] Strength Ambient air control and 3
exposure groups; relevant
route of administration
and duration of exposure.
Information on chemical
source provided. Inhalation
chamber characterized;
dynamic airﬂow; mean
chamber concentrations
reported.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups prior to mating.
Adequate sample size (27
litters/group).
GLP, guideline prenatal
devtox study. All
litters/fetuses evaluated.
Fetal examination
conducted without
knowledge of treatment
group.
Relevant maternal and
fetal endpoints assessed.
Fetal visceral exam used
Staples method
(examination of internal
cardiac morphology) plus
free-hand sectioning of
head. Skeletal exam
evaluated both bone and
cartilage development.
Appropriate statistical
methods; litter used as
unit of statistical analysis.
Summary data for
maternal and fetal
endpoints reported.
Limitation Whole body exposure. Individual maternal and
fetal data NR.
Dorfmueller et al. [21] Strength Filtered ambient air control
and 3 groups with a single
high dose exposure level
over various durations;
relevant route of
administration and
duration of exposure.
Information on chemical
source provided. Inhalation
chamber characterized;
dynamic airﬂow; chamber
concentrations monitored
at 13 min  intervals.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups. Adequate sample
size (subset of 15
litters/group assigned to
c-section).
Study included groups
with exposures and
assessments similar to
EPA guideline.
Relevant maternal and
fetal endpoints assessed.
Fetal visceral exam used
Wilson technique
(free-hand sectioning of
fetuses). Skeletal exam
evaluated bone
development.
Appropriate methods;
litter used as unit of
statistical analysis.
Summary data for
maternal and fetal
endpoints reported.
Limitation Technical grade solvent
containing 99% TCE and
0.2% epichlorhydrin. Whole
body exposure.
Information on facility
certiﬁcation NR.
Non-random assignment
(based upon uterine
position) of 8
fetuses/litter to either
skeletal or visceral exam;
disposition of additional
fetuses NR
Fetal visceral exam did
not include in situ
dissection and
examination of cardiac
morphology.
Individual maternal and
fetal data NR.
Hardin  et al. [39] Strength Control and 1 exposure
group; relevant route of
administration and
duration of exposure.
Species, strain, sex,
reported. Adequate sample
size: target was 30 rats or
20 rabbits/group; report
indicated difﬁculties in
some studies resulting in
15 rabbits/group.
Study design similar to
EPA guideline.
Relevant maternal and
fetal endpoints assessed.
Fetal visceral exam used
Wilson technique
(free-hand sectioning of
1/2 to 2/3 fetuses/litter).
Skeletal exam evaluated
bone development.
Limitation Whole body exposure.
Chemical characterization
and source NR. Control
exposure not
characterized. Exposure
chamber, conditions, and
measurement of
concentration NR. Duration
of exposure not
characterized for TCE.
Maternal source,
age/lifestage/BW, and
random assignment to test
groups NR. Exact sample
size NR.
Information on facility
certiﬁcation NR. The
report summarized
developmental toxicity
testing for 9 chemicals
including TCE; speciﬁc
study design details for
each test substance were
NR.
The exact distribution of
fetuses for visceral and
skeletal evaluation NR.
Random assignment to
evaluation procedure NR.
Whether Staples
dissection method
(examination of internal
cardiac morphology) was
used in the TCE studies
was NR.
Statistical methods NR. Study design details NR.
Summary data for
maternal and fetal
endpoints NR. With the
exception of a brain
malformation in 2 rabbit
fetuses, study ﬁndings for
TCE were not discussed.
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Reference Exposure Quality Test Subjects Study Design Endpoints Data & Statistics Reporting
Healy et al. [42] Strength Ambient air control and 1
exposure group; relevant
route of administration
and duration of exposure.
Information on chemical
source provided. Inhalation
chamber characterized;
dynamic airﬂow; chamber
concentrations monitored
continuously.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups after mating.
Adequate sample size (31
control, 32 treated litters).
Study design similar to
EPA guideline. All fetuses
assessed for external,
visceral, and skeletal
effects.
Relevant maternal and
fetal endpoints assessed.
Fetal visceral exam used
fresh dissection and
examination of internal
organs. Skeletal exam
evaluated bone
development.
Appropriate statistical
methods for some
outcomes.
Summary data for
maternal and fetal
endpoints reported.
Limitation Whole body exposure.
Chamber concentration
data NR.
Information on facility
certiﬁcation NR. Exposure
duration (4 h/day, GD
8–21) was insufﬁcient in
daily duration and did not
cover the entire period of
organogenesis. No
indication that fetuses
were examined without
knowledge of treatment
group.
Fetal visceral examination
did not include brain or
reproductive organs. Fetal
cardiac exam did not
include internal
morphology.
No indication that litter
was used as unit of
statistical analysis for
fetal anomalies.
Individual maternal and
fetal data NR.
Schwetz  et al. [74] Strength Filtered ambient air control
and 1 exposure group;
relevant route of
administration and
duration of exposure.
Information on chemical
source provided. Inhalation
chamber characterized;
dynamic airﬂow; chamber
concentrations monitored
continuously and mean
concentrations reported.
Species, strain, sex,
age/lifestage/BW, reported.
Adequate sample size (30
control, 18 treated rats; 26
control, 12 treated mice).
Study design similar to
EPA guideline. All fetuses
assessed for external,
visceral, and skeletal
effects.
Relevant maternal and
fetal endpoints assessed.
Fetal visceral exam used
Wilson technique
(free-hand sectioning of
1/2 fetuses/litter) and
skeletal exam evaluated
bone development in ½
fetuses/litter. One
fetus/litter randomly
selected for whole-body
sagittal sectioning and
microscopic examination.
Appropriate statistical
methods; litter used as
unit of statistical analysis.
Summary data for some
maternal and fetal
endpoints reported.
Limitation Whole body exposure.
99.2% TCE; 0.76% inhibitors
and impurities.
Animal source NR. Random
assignment of maternal
animals to test groups NR.
Information on facility
certiﬁcation NR. No
indication that fetuses
were examined without
knowledge of treatment
group.
Random assignment of
fetuses to visceral or
skeletal evaluation
procedure NR. The use of
in  situ dissection and
examination of cardiac
morphology NR.
Maternal BW data NR.
Individual maternal and
fetal data NR.
In  Vivo Mammalian Oral Studies
Cosby and Dukelow
[18]
Strength Vehicle control and 2
treatment groups; relevant
route of administration
and duration of exposure.
Information on chemical
source provided.
Formulations mixed
immediately prior to
dosing; formulation
methods enhanced
stability; concentration
tested. Dose
volume = 0.2 mL.
Species, strain, source, sex,
age/lifestage/BW, reported.
Adequate sample size
(7–12 litters/control
cohort,
10–12litters/treated
cohort).
Study designed to
examine effects on
reproductive success and
offspring birth and
postnatal outcome.
Relevant maternal and
offspring endpoints
assessed. All pups
examined. Random
selection of litters for PND
43 postmortem
evaluation.
Statistical analysis of data
conducted.
Summary gestation index
and litter size data
reported.
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Limitation Concentration data NR Females non-randomly
assigned to test groups
(based on BW)  after
mating.
Corn oil vehicle. Dose
duration (5 daily prenatal
doses, initiating at GD 1,
6, or 11) do not cover the
entire period of
organogenesis. No
indication that fetuses
were examined without
knowledge of treatment
group.
Litter size standardization
was implemented on PND
1  and 22; no indication of
random selection of pups
for culling.
Statistical methods not
fully characterized.
Replicate treatment data
sets were pooled for tests
of statistical signiﬁcance.
No indication that the
litter was  used as unit of
statistical analysis.
Maternal BW and
postmortem data
NR. Offspring weight,
length, external
abnormalities, and
postmortem data NR.
Dawson  et al. [19] Strength Vehicle control and 2
treatment groups per
metabolite; relevant
duration of exposure.
Information on chemical
source provided.
Species, strain, source, sex,
age/lifestage/BW, reported.
Adequate sample size
(10–17 dams/group).
Study designed
speciﬁcally to assess fetal
cardiac defects.
Detailed fetal cardiac
dissection, preservation,
and examination methods
provided.
Relevant fetal endpoints
assessed. Fetal cardiac
exam conducted without
knowledge of treatment
group. Positive cardiac
ﬁndings were conﬁrmed
by unanimous agreement
of study authors.
Individual and summary
incidences of fetal cardiac
defects reported.
Limitation Route of administra-
tion = intrauterine injection
(not relevant to
environmental exposures).
Surgery was  performed on
GD 7 pregnant rats to
insert osmotic pump. DCA
and TCA purity, stability,
concentration data NR
No indication of random
assignment to test groups.
No information on
laboratory certiﬁcation
status. Duration of study
conduct NR.
Maternal observations
consisted of monitoring
for adverse consequences
of surgery.
Statistical methods NR
although signiﬁcance was
reported.
Fetal BW and length NR;
variance for mean
implant and resorption
data not shown in bar
graph; litter incidence of
cardiac defects NR.
Dawson et al. [20]a Strength Vehicle control and 2
treatment groups; relevant
route of administration
and duration of exposure.
Information on chemical
source provided; stability
and concentration tested;
formulation methods
enhanced stability.
Drinking water
formulations mixed daily.
WC  measured daily. Dose
calculations based on
consumption,
concentration, and TCE
breakdown rates.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups after mating.
AAALAC-certiﬁed facility.
Study designed
speciﬁcally to assess fetal
cardiac defects.
Detailed fetal cardiac
dissection, preservation,
and examination methods
provided.
Relevant maternal and
fetal endpoints assessed.
Fetal cardiac exam
conducted without
knowledge of treatment
group. Positive cardiac
ﬁndings were conﬁrmed
by unanimous agreement
of study authors.
Individual fetal cardiac
defect data were provided
to EPA and analyzed using
the litter as unit of
statistical analysis.
Maternal endpoints
reported for treated
groups; individual fetal
cardiac defects reported;
litter associations for
cardiac defects were
provided to EPA.
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Limitation Vehicle = tap water
(unknown contaminants);
possible imprecision in WC
values since dams were
group housed; TCE purity,
stability, concentration
data NR
No. of fetuses/group
reported, but not number
of litters;b however,
Johnson et al. reported the
number of litters in the
control (n = 13–15) and TCE
groups (n = 9–13).a
Study conducted over
period of 3 years in 2
cohorts; study dates for
control animals
overlapped treated
groups but were not
exactly concurrent.
Fetal evaluation of
non-cardiac ﬁndings
(visceral and skeletal) was
not described.
Statistical analysis
conducted under contract
by study authors did not
use litter as unit of
statistical analysis.b
Maternal FC, WC,  clin obs,
placental wt, necropsy
data NR; fetal BW and
length, external and
skeletal data, and
non-cardiac visceral data
NR; variance for mean
implant and resorption
data NR; cardiac defects
were not associated with
litter of origin.b
Epstein et al. [27] Strength 3 vehicle control groups
and 3 treatment groups per
exposure paradigm;
relevant route of
administration and
durations of exposure
(designed to identify
critical developmental
windows for cardiac
defects). Information on
chemical source provided;
purity and stability
conﬁrmed; storage
procedures enhanced
stability.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups after mating.
Adequate sample size
(11–17 controls, 7–10
treated/group).
Study designed to identify
critical windows of effects
on cardiac development.
Relevant maternal and
fetal endpoints assessed.
Statistical analysis of data
conducted.
Incidence and mean (and
%/litter) fetal cardiac data
reported.
Limitation Information on facility
certiﬁcation NR. Study
was conducted in 3
cohorts; dates of study
conduct NR.
No indication that
offspring were examined
without knowledge of
treatment group.
No indication if the litter
was used as unit of
statistical analysis.
Variance NR for mean
data. Maternal data NR.
Individual and summary
implantation, resorption,
fetal BW,  length, sex, and
external evaluation data
NR.
Fisher  et al. [28] Strength 2 vehicle controls and 1
treatment group per test
substance; relevant route
of administration and
duration of exposure.
Information on chemical
source provided; weekly
stability and concentration
tested; storage procedures
enhanced stability. Dose
volumes were based on
maternal BW.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups after mating.
Adequate sample size
(19–25 litters/vehicle
control or treated group,
12 litters/positive control
group).
AAALAC-certiﬁed facility.
Study designed
speciﬁcally to assess fetal
cardiac defects.
All litters/fetuses
evaluated. Fetuses were
examined without
knowledge of treatment
group. Detailed fetal
cardiac dissection,
preservation, and
examination methods
provided. Positive control
group was included.
Cardiac dissection and
evaluation team included
Dr. Paula Johnson.
Relevant maternal and
fetal endpoints assessed.
Fetal cardiac exam
conducted without
knowledge of treatment
group. Cardiac evaluation
procedures were the
same as those used in
Dawson et al. [20] and
Johnson et al. [51]; hearts
were also stained with
hematoxylin.
Appropriate statistical
methods; litter used as
unit of statistical analysis.
Summary data for
maternal and fetal
endpoints reported.
Limitation Stability schedule and data
NR. Concentration not
tested.
Individual maternal and
fetal data NR.
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Johnson et al. [49] Strength Vehicle control and 1
treatment level for each of
7 metabolites; relevant
route of administration
and duration of exposure.
Administration methods
enhanced stability.
Drinking water
formulations mixed daily.
WC  measured daily.
Species, strain, source, sex,
age/lifestage/BW, reported.
Number of dams (litters)
reported: (55 controls,
10–20/high dose groups
(4); 3–4/low dose groups
(3).
AAALAC-certiﬁed facility.
Study designed
speciﬁcally to assess fetal
cardiac defects.
Detailed fetal cardiac
dissection, preservation,
and examination methods
provided.
Relevant maternal and
fetal endpoints assessed.
Fetal cardiac exam
conducted without
knowledge of treatment
group. Positive cardiac
ﬁndings were conﬁrmed
by unanimous agreement
of study authors.
Statistical methods
provided. The litter was
used as unit of statistical
analysis.
Maternal mean WC,  BW
and uterine data reported;
fetal mean resorptions
and incidence of cardiac
defects reported.
Limitation Information on source of
test substances NR. WC
values were for group
housed dams(4/cage);
purity, stability,
concentration data NR
No indication that dams
were randomly assigned to
test groups. Control group
was  a combined cohort.b
Study dates for control
animals overlapped
treated groups but were
not all concurrent.b
Fetal evaluation of
non-cardiac visceral
ﬁndings was not
described.
Fetal BW and length,
external data, and
non-cardiac visceral data
NR; litter incidence of
cardiac malformations
NR; variance for mean
implantation and
resorption data NR.
Johnson et al. [51,52] Strength Vehicle control and 4
treatment groups; relevant
route of administration
and duration of exposure.
Information on chemical
source provided; stability
and concentration tested;
formulation methods
enhanced stability.
Drinking water
formulations mixed daily.
WC  measured daily. Dose
calculations based on
consumption,
concentration, and TCE
breakdown rates.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups after mating.
Number of fetuses and
litters, as well as dates of
study conduct, are
provided for each control
and treated cohort. Control
cohorts: n = 6–15); total
control n = 55; TCE group
cohorts: n = 9–13. Analysis
of control cohort data was
used to justify combining
control cohorts.
AAALAC-certiﬁed facility.
Study designed
speciﬁcally to assess fetal
cardiac defects.
Detailed fetal dissection
and cardiac preservation
methods.
All fetuses examined
without knowledge of
treatment group.
Fetal evaluation methods
were consistent across
cohorts.
Relevant maternal and
fetal endpoints assessed.
Fetal cardiac exam
conducted without
knowledge of treatment
group. Positive cardiac
ﬁndings were conﬁrmed
by unanimous agreement
of study authors.
Individual fetal cardiac
defect data were provided
to EPA and analyzed using
the litter as unit of
statistical analysis.
Individual fetal cardiac
defects reported; litter
associations for cardiac
defects and maternal
endpoints for treated
groups; were provided to
EPA.
Limitation TCE purity, stability,
concentration NR
Data derived from Dawson
et al. [20] study were
treated with tap water
vehicle (unknown
contaminants).
Some gaps in concurrency
of treated groups and their
controls resulted in part
from random assignment
procedures.
Animals were placed on
study in small cohorts.
Study conducted over
period of 6 years in 5
cohorts; study data from
1994 to 1995 were
combined with Dawson
et al. [20] gestation-only
data from 1989 to 1993
plus control data from
metabolite studies
conducted from 1992 to
1994. Study dates for
control animals
overlapped treated
groups but were not
exactly concurrent.
Fetal evaluation of
non-cardiac ﬁndings
(visceral and skeletal) was
not described.
Statistical analysis
conducted under contract
by study authors did not
consider litter effects.b
Maternal BW,  FC, WC,  clin
obs, placental wt,
necropsy data,
resorptions and
implantations NR; fetal
BW and length, external
and skeletal data, and
non-cardiac visceral data
NR; cardiac defects
reported per 100-fetus
basis, but not associated
with litter of origin.b
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Narotsky et al. [62] Strength Vehicle control and 4
treatment groups; relevant
route  of administration and
duration of exposure.
Information on chemical
source provided; purity
reported. Storage methods
enhanced stability. Dose
volumes based on GD6 BW.
Species, strain, source, sex,
age/lifestage/BW, reported.
Adequate sample size (8–12
dams/group).
AAALAC-certiﬁed facility.
Modiﬁed Chernoff and
Kavlock devtox screening
study. Visceral examination
of dead pups consisted of
Wilson free-hand section of
head and dissection of
thoracic and abdominal
organs.
Relevant maternal and fetal
endpoints assessed.
Appropriate statistical
methods; litter used as unit
of  statistical analysis.
Summary data for maternal
and  fetal endpoints
reported.
Limitation  Stability and concentration
analysis NR
Random assignment to test
group NR
Protocol did not require
visceral or skeletal
evaluation of live pups.
Individual maternal and
fetal  data NR.
Narotsky  and Kavlock
[61]
Strength Vehicle control and 2
treatment groups; relevant
route  of administration and
duration of exposure.
Information on chemical
source provided; purity
reported. Storage methods
enhanced stability. Dose
volumes based on GD6 BW.
Species, strain, source, sex,
age/lifestage/BW, reported.
Assignment to test group
after  mating using unbiased
procedure to ensure
homogenous distribution of
BWs. Adequate sample size
(21 control, 16–17
treated/group).
AAALAC-certiﬁed facility.
Modiﬁed Chernoff and
Kavlock devtox screening
study. Visceral examination
of dead pups consisted of
Wilson free-hand section of
head and dissection of
thoracic and abdominal
organs.
Relevant maternal and fetal
endpoints assessed.
Appropriate statistical
methods; litter used as unit
of  statistical analysis.
Summary data for maternal
and  fetal endpoints
reported.
Limitation  Stability and concentration
analysis NR
Protocol did not require
visceral or skeletal
evaluation of live pups.
Individual maternal and
fetal  data NR.
Smith  et al. [78] Strength Vehicle control and 4
treatment groups; relevant
route  of administration and
duration of exposure.
Information on chemical
source provided; purity,
stability and concentration
conﬁrmed.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups. Adequate sample
size  (26 controls, 20–21
treated/group).
Study design similar to EPA
guideline. All fetuses
assessed for external
ﬁndings; 2/3 fetuses
assigned to visceral exam,
and  1/3 fetuses assigned to
skeletal exam (bone and
cartilage).
Relevant maternal and fetal
endpoints assessed.
Statistical analysis of data
conducted.
Maternal BW, uterine, and
organ weight data reported.
Mean (±SD) fetal weight,
length, and malformations
reported; fetal
malformation incidence
data reported.
Limitation  Stability and concentration
data NR
Information on facility
certiﬁcation NR. No
indication whether fetuses
were  randomly assigned to
visceral or skeletal
evaluation.
No indication that offspring
were examined without
knowledge of treatment
group.
No indication if  the litter
was used as unit of
statistical analysis.
Individual maternal and
fetal  data NR.
Smith  et al. [79] Strength Vehicle control and 7
treatment groups; relevant
route  of administration and
duration of exposure.
Information on chemical
source provided; purity,
stability and concentration
conﬁrmed.
Species, strain, source, sex,
age/lifestage/BW, reported.
Randomly assigned to test
groups. Adequate sample
size  (20 controls, 19–21
treated/group).
Study design similar to EPA
guideline. All fetuses
assessed for external
ﬁndings; 2/3 fetuses
assigned to visceral exam,
and  1/3 fetuses assigned to
skeletal exam (bone and
cartilage).
Relevant maternal and fetal
endpoints assessed.
Statistical analysis of data
conducted.
Maternal BW and uterine
data reported. Mean (±SD)
fetal weight, length, and
malformations reported;
fetal  malformation
incidence data reported.
Limitation  Stability and concentration
data NR
Information on facility
certiﬁcation NR. No
information provided
regarding whether fetuses
were  randomly assigned to
visceral or skeletal
evaluation.
No indication that offspring
were examined without
knowledge of treatment
group.
No indication if  the litter
was used as unit of
statistical analysis.
Individual maternal and
fetal  data NR.
NR = Not Reported; BW = body weight; FC = food consumption; WC = water consumption.
a For Dawson et al. [20] and Johnson et al. [49], a number of study details were also provided in Johnson et al. [51,53,52]; Johnson [47].
b Additional information and/or data provided to EPA mitigated the limitations or uncertainties identiﬁed in the study report.
S.L. Makris et al. / Reproductive Toxicology 65 (2016) 321–358 339
1
10
100
1000
1000 0
Ha
rd
in
 e
t a
l.,
 1
98
1
N
ew
 Z
ea
la
nd
, R
ab
bi
t
Do
rf
m
ue
lle
r e
t a
l.,
 1
97
0
Lo
ng
-E
va
ns
, R
at
He
al
y 
e t
 a
l.,
 1
98
2
W
ist
ar
, R
at
Ca
rn
ey
 e
t a
l.,
 2
00
6
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Ha
rd
in
 e
t a
l.,
 1
98
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Sc
hw
et
z e
t a
l.,
 1
97
5
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Sc
hw
et
z e
t a
l.,
 1
97
5
Sw
iss
-W
eb
st
er
, M
ou
se
Ha
rd
in
 e
t a
l.,
 1
98
1
N
ew
 Z
ea
la
nd
, R
ab
bi
t
Do
rf
m
ue
lle
r e
t a
l.,
 1
97
0
Lo
ng
-E
va
ns
, R
at
He
al
y 
et
 a
l.,
 1
98
2
W
ist
ar
, R
at
Ca
rn
ey
 e
t a
l.,
 2
00
6
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Ha
rd
in
 e
t a
l.,
 1
98
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Sc
hw
et
z e
t a
l.,
 1
97
5
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Sc
hw
et
z e
t a
l.,
 1
97
5
Sw
iss
-W
eb
st
er
, M
ou
se
Ha
rd
in
 e
t a
l.,
 1
98
1
N
ew
 Z
ea
la
nd
, R
ab
bi
t
Do
rf
m
ue
lle
r e
t a
l.,
 1
97
0
Lo
ng
-E
va
ns
, R
at
He
al
y 
et
 a
l.,
 1
98
2
W
ist
ar
, R
at
Ca
rn
ey
 e
t a
l.,
 2
00
6
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Ha
rd
in
 e
t a
l.,
 1
98
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Sc
hw
e t
z e
t a
l.,
 1
97
5
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Sc
hw
e t
z e
t a
l.,
 1
97
5
Sw
iss
-W
eb
st
er
, M
ou
se
↓ Oﬀspri ng Survival ↓Oﬀspri ng Growth Al tered Morph ologic al Development
Co
nc
en
tr
a
on
 (m
g/
m
3 )
LOAE L NOAEL Doses > LOAEL Doses < NOAE L
Fig. 2. TCE inhalation developmental toxicology studies. Effects on fetal/offspring survival, growth, and morphology following maternal inhalation exposures to TCE during
gestation. Boxes indicate the doses at which maternal toxicity was  observed.
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oxes  indicate the doses at which maternal toxicity was observed. 1Maternal toxicit
elevant to cardiac defects are presented in the TCE IRIS assessment
87], Tables 5–18).
Several studies were conducted in rats to examine the effects
f developmental exposures to the TCE oxidative metabolites,
CA and TCA. Studies by Smith et al. [79] and Epstein et al.
27] observed cardiac defects following gavage administration of
CA during pregnancy. Smith et al. [78] and Johnson et al. [49]
eported cardiac defects with TCA exposures administered during
estation via gavage or drinking water, respectively. However, a
tudy by Fisher et al. [28] did not detect cardiac defects follow-
ng gavage administration of DCA or TCA on GD 6–15. All of these
tudies used dissection methods that were designed to visualize
he internal structures of the fetal heart. Other TCE metabolites
ere evaluated by Johnson et al. [49] and found not to elicit
ardiac malformations following developmental exposures (i.e.,
arboxymethyl cysteine, dichloroacetaldehyde, dichloroethylene,wth, and morphology following maternal oral exposures to TCE during gestation.
 not reported in Johnson et al. [51]. * Doses at which cardiac defects were observed.
dichlorovinyl cysteine, monochloroacetic acid, trichloroacetalde-
hyde, and trichloroethanol). Although the proximate toxicant
which causes cardiac defects has not been identiﬁed, a recent study
[6] identiﬁed 5-(1,2-dichlorovinyl)-l-cysteine as a key metabolite
in placental effects of TCE, suggesting that further consideration of
TCE metabolites may  be warranted.
3.1.2.4. In ovo avian studies. Several studies examined cardiac
development following in ovo administration of TCE to chicken
embryos [72,24,23,57]. Abnormalities of cardiac structure and/or
function were observed in each of these studies, at doses as low
as 2–8 ppb. Defects in valvulo-septal development were similar to
those that have been observed in rodents and humans, which is
coherent given that early stages of cardiac development are similar
across species [63].
340 S.L. Makris et al. / Reproductive Toxicology 65 (2016) 321–358
*
*
*
*
1
10
100
1000
10000
Sm
ith
 e
t a
l.,
 1
99
2
Lo
ng
 E
va
ns
, R
at
Fi
sh
er
 e
t a
l.,
 2
00
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Ep
st
ei
n 
et
 a
l.,
 1
99
2¹
Lo
ng
 E
va
ns
, R
at
Sm
ith
 e
t a
l.,
 1
99
2
Lo
ng
 E
va
ns
, R
at
Fi
sh
er
 e
t a
l.,
 2
00
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Ep
st
ei
n 
et
 a
l.,
 1
9 9
2¹
Lo
ng
 E
va
ns
, R
at
Sm
ith
 e
t a
l.,
 1
99
2
Lo
ng
 E
va
ns
, R
at
Fi
sh
er
 e
t a
l.,
 2
00
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Ep
st
ei
n 
et
 a
l.,
 1
9 9
2¹
Lo
ng
 E
va
ns
, R
at
Sm
ith
 e
t a
l.,
 1
98
9
Lo
ng
 E
va
ns
, R
at
Fi
sh
er
 e
t a
l.,
 2
00
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Jo
hn
so
n 
e t
 a
l.,
 1
99
8 
a,
b
Lo
ng
 E
va
ns
, r
at
Sm
ith
 e
t a
l.,
 1
98
9
Lo
ng
 E
va
ns
, R
at
Fi
sh
er
 e
t a
l.,
 2
00
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Jo
hn
so
n 
e t
 a
l.,
 1
99
8 
a,
b
Lo
ng
 E
va
ns
, r
at
Sm
ith
 e
t a
l.,
 1
98
9
Lo
ng
 E
va
ns
, R
at
Fi
sh
er
 e
t a
l.,
 2
00
1
Sp
ra
gu
e-
Da
w
le
y,
 R
at
Jo
hn
so
n 
et
 a
l.,
 1
99
8 
a,
b
Lo
ng
 E
va
ns
, r
at
↓ Survival ↓ Growth Al tered Morph ologic al
Development
↓  Survival ↓Growth Al tered Morph ologic al
Development
DCA TCA
Do
se
 (m
g/
kg
-d
ay
)
LOA EL NOA EL Doses > LOA EL Doses < NOA EL
*
*
*
*
**
*
F  survi
D  was o
c
3
i
u
b
t
o
m
3
i
b
a
d
i
a
h
t
w
c
ﬁ
i
d
D
i
t
t
1
b
s
y
m
t
c
f
p
[
r
dig. 4. DCA and TCA oral developmental toxicology studies. Effects on fetal/offspring
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ardiac defects were observed.
.1.2.5. In vitro assays. Whole embryo culture studies that exam-
ned cardiac development were conducted by Hunter et al. [44]
sing 3–6 somite mouse embryos exposed to DCA or TCA and
y Mishima et al. [60] using HH 13-14 chicken embryos exposed
o TCE. Dose-related alterations in cardiac development were
bserved in both of these models, although at high (not environ-
entally relevant) doses.
.1.2.6. Evaluation of cardiac defects in the animal toxicology stud-
es. As described, alterations in fetal cardiac development have
een observed in rodent studies following in utero exposure to TCE
nd its oxidative metabolites. These ﬁndings are supported by the
etection of cardiac anomalies in chicken embryos exposed to TCE
n ovo, and in whole embryo cultures (mouse and chicken) of TCE
nd/or its metabolites. In spite of the concordant evidence that TCE
as been associated with cardiac defects, controversy centers on
he studies by Johnson et al. [51] and Dawson et al. [20], especially
ith respect to the study design and methods, reporting inadequa-
ies, dose-response characteristics, and the lack of cardiac defect
ndings in other laboratory studies in rodents following gavage or
nhalation exposures of TCE during development.
The Johnson et al. [51] publication reported the results of TCE
rinking water exposures on fetal cardiac development in Sprague-
awley rats from a 6-year-long academic research program. It
ncluded data on two TCE treatment groups studied in 1989–1991
hat had previously been published by Dawson et al. [20], plus
he data from two lower dose TCE treatment groups studied in
994–1995. Cardiac malformation incidence data were compared
etween treated groups and combined control data from cohorts
tudied concurrent to treated groups over the course of the 6-
ear research program, including controls from studies on TCE
etabolites, published in Johnson et al. [49]. Other information on
he TCE studies reported in Johnson et al. [51] included published
ommunications [40,50], errata [53,52], and individual cardiac mal-
ormation ﬁndings and evaluation methods provided to EPA by the
rimary study author (Dr. Paula Johnson, personal communications
47,48]). The Johnson et al. [51] paper summarized the combined
esults from the studies that administered TCE to pregnant rats at
oses of 2.5 ppb, 250 ppb, 1.5 ppm, and 1100 ppm in drinking waterval, growth, and morphology following maternal oral exposures to TCE metabolites,
bserved. 1Maternal toxicity was not reported in Epstein et al. [27]. *Doses at which
throughout gestation. Fetal cardiac defects, primarily valvular and
septal anomalies, were observed at ≥250 ppb.
The limitations and strengths of the toxicological studies were
identiﬁed (details provided in Table 4). Limitations identiﬁed in the
evaluation of the Johnson et al. [51] and Dawson et al. [20] studies
presented here are consistent with the study design and report-
ing issues identiﬁed in the IRIS assessment [87], peer-reviewed
publications such as Hardin et al. [38] and Watson et al. [90],
and public comments submitted to the U.S. EPA [1]. The corre-
sponding author for Johnson et al. [51] provided clariﬁcation on
a number of topics and a detailed description of study methods
beyond what had been previously published, including veriﬁcation
that concurrent controls were used for each of the treated groups
(Fig. 5), information on fetal randomization and blinded cardiac
evaluation procedures, and details of animal husbandry (Dr. Paula
Johnson, personal communication, 2014). Subsequent to these dis-
cussions, the study author published an errata [53] to update the
public record regarding methodological issues for Johnson et al.
[51]. This information served to increase conﬁdence in the study
conduct and results. However, some study reporting and method-
ological details remain unknown, e.g., the precise dates that each
individual control animal was  on study, maternal body weight/food
consumption and clinical observation data, and the detailed results
of analytical chemistry testing for dose concentration. Additional
possible sources of uncertainty identiﬁed for these studies include
that the research was conducted over a 6-year period, that com-
bined control data were used for comparison to treated groups,
and that exposure characterization may  be imprecise because tap
(rather than distilled) drinking water was  used in the Dawson et al.
[20] study and because TCE intake values were derived from water
consumption measures of group-housed animals. On the other
hand, the strengths of this study include the examination of fetal
hearts without knowledge of treatment (or control) group, stan-
dardized methods of fetal evaluation, examination of the gross (in
situ) and internal structure of the fetal hearts by a group of three
senior researchers/co-authors (P. Johnson, B. Dawson, and S. Gold-
berg), conﬁrmation of cardiac anomalies by consensus agreement.
In addition, individual fetal and litter cardiac abnormality data for
treated groups were shared with EPA (Dr. Paula Johnson, personal
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Fig. 5. Control vs. TCE treatment groups and dates of exposure. During the duration of the University of Arizona (UA) research program on TCE (1989–1995), a number of
developmental toxicology studies were conducted on TCE and its metabolites. Control animals (red blocks) were on study when treated animals (blue blocks) were being
exposed. The blocks are general representations of time frames and are not presented to exact scale. The dates that cohorts of animals were on study (as well as dose levels
and  the number of dams/litters for each cohort) are shown. In three cases, information on the exact month and day of animal receipt was not available (indicated by dotted
lines).  Exclusively pregnancy-only TCE-treated groups are included in this ﬁgure; however, other treatment regimens were also being conducted during the time period of
6/12/89  to 10/6/95 (i.e., 3 months pre-pregnancy-only, 2 months pre-pregnancy + pregnancy). Additionally, during this time period, TCE metabolites and other toxicokinetically
r , mono
d (DCVC
w E-trea
c
c
d
p
[
s
w
i
J
F
t
[
w
o
g
n
t
m
i
l
e
i
a
s
o
[
T
t
T
i
a
o
I
w
d
s
a
c
u
eelated chemicals were studied: dichloroacetic acid (DCA), trichloroacetic acid (TCA)
ichloroacetaldehyde (DCAld), carboxy methylcystine (CMC), dichlorovinyl cystine 
ere  combined for statistical comparison with incidence data for pregnancy-only TC
ommunication (2008)), thereby facilitating independent statisti-
al analysis of the data.
Inconsistencies in the results of studies that assessed car-
iac development in rodents have been raised as an issue of
articular concern. In the case of a number of these studies
61,62,18,42,39,21,74], a variety of animal species and strains,
ources, and testing protocols were used (summarized in Table 5a),
hich precludes direct comparisons. For several of the older stud-
es, information that would allow a valid comparison with the
ohnson et al. [51] and Dawson et al. [20] studies is not reported.
or example, detailed procedural details regarding fetal evalua-
ion were not provided for Schwetz et al. [74], Dorfmueller et al.
21], Healy et al. [42], and Hardin et al. [39]. There is no indication
hether fetuses were selected randomly for visceral evaluation,
r whether they were examined without knowledge of treatment
roup (blinded assessment). Fetal cardiac evaluation methods were
ot elucidated in any detail, and the performance of fresh dissec-
ion of the heart to evaluate internal cardiac morphology was not
entioned. Hardin et al. [39] reported virtually no methodological
nformation. In some studies, differences in overall study design
imited meaningful cross-study comparison, e.g., due to limited
xposure durations [18] or the evaluation of delivered PND 1 pups
nstead of fetuses [61,62]. The studies reported by Fisher et al. [28]
nd Carney et al. [15] were well-conducted developmental toxicity
tudies in rats and utilized procedures that facilitated evaluation
f fetal cardiac morphology. Fisher et al. [28] and Carney et al.
15] did not observe treatment-related cardiac defects following
CE gavage or inhalation exposures, respectively, during gesta-
ion. Detailed examination of the study protocols (summarized in
able 5b) identiﬁed several variations in study design and conduct,
ncluding but not limited to differences in route of administration,
nd these differences may  have contributed to the different study
utcome as compared to Johnson et al. [51] and Dawson et al. [20].
n the case of the Fisher et al. [28] study, as previously noted, care
as taken to follow the Johnson et al. [51] fetal evaluation proce-
ures as closely as possible, yet a number of other differences in
tudy design and conduct remained. For example, the source of the
nimals, the route of exposure, the vehicle/control substance, fetal
ardiac tissue preservation methods, and some fetal cardiac eval-
ation procedures were different. A comparison of typical cardiac
valuation techniques used in developmental toxicology studies,chloroacetic acid (MCAA), trichloroethanol (TCEth), trichloroacetaldehyde (TCAld),
), dichloroethylene (DCE). The control animal cardiac malformation incidence data
ted groups. Sources of information used to compile this ﬁgure: [53,52,50,51,49,20].
illustrating some potential differences in resolution of abnormal-
ities in the fetal heart, is presented in Table 6. This includes the
procedures used by Carney et al. [15] and the procedures used by
Dawson et al. [20], Johnson et al. [49], and Johnson et al. [51], as well
as by Fisher et al. [28]. One possibility is that the procedural differ-
ences in fetal cardiac evaluation techniques could have contributed
to differences in study outcome [90]. However, that explanation is
not supported by two  facts. First, the detailed description of the
cardiac dissection and evaluation techniques (as reported in Daw-
son et al. [20] is sufﬁciently comparable to the procedures used
by Carney et al. [15] (summarized in Table 6) to have facilitated
visualization of overt cardiac malformations such as septal defects.
Secondly, Fisher et al. [28] used the same cardiac evaluation tech-
niques reported by Dawson et al. [20], Johnson et al. [49], and
Johnson et al. [51], evaluated fetuses collaboratively with Dr.  John-
son, and yet did not detect treatment-related incidences of cardiac
defects.
In summary, Johnson et al. [51] and Dawson et al. [20] observed
cardiac defects in fetal rats after gestational drinking water expo-
sures to TCE. These ﬁndings have not been conﬁrmed in studies with
exposures to TCE during gestation that were conducted by other
laboratories. However, none of the other studies have repeated
precisely the same study design used by Johnson et al. [51] and
Dawson et al. [20]. Differences in study methods such as the route
of exposure, vehicle, source or strain of animals, or other unknown
factors may  have contributed to differences in the detection of car-
diac malformations, and at this point in time, it would be impossible
to identify the speciﬁc reason. Designing and conducting an exact
replica of the Johnson et al. [51] study might be very difﬁcult, if not
impossible. For example, it is possible that the study animals used
by Dawson et al. [19] and Johnson et al. [51] in the University of
Arizona (UA) research program on TCE in drinking water may  have
been particularly susceptible to perturbation of cardiac develop-
ment by TCE and its metabolites. The possibility of genetic drift
in the strain/source of rats over the past 10–20 years might pre-
clude designing and conducting a study with comparable results.
Yet, such a susceptibility in the animal models used by Dawson et al.
[20] and Johnson et al. [51] might have rendered those studies more
(or less) predictive of responses in susceptible individuals in the
human population, a difﬁcult assumption to validate. In humans,
cardiovascular malformations are common birth defects with both
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Table 5a
Comparison of Methods Reported for Prenatal Developmental Toxicity Studies with TCE.
Schwetz  et  al.  [74]  Dorfmueller  et  al.
[21]
Hardin  et  al.  [39]  Healy  et  al.  [42]  Cosby  and
Dukelow  [18]
Narotsky  and
Kavlock  [61]
Narotsky  et  al.
[62]
Study  Description/Objective
Guideline-type  [GT]  or  research  [R]  protocol GT  GT  R  GT  GT  GT  R  R  R
Test  Subjects
Species  Rat  Mouse  Rat  Rat  Rabbit  Rat  Mouse  Rat  Rat
Strain  SD  SW  LE  WIS or  SD  NZW  WIS B6D2F1  Fischer  344  Fischer  344
Source  (company)  NR  NR  CRL  NR  NR  NR  Jackson  Harlan  Harlan
Source  (location) NR  NR  NR NR  NR  NR  Bar  Harbor,  ME  Indianapolis,  IN  Indianapolis,  IN
Dates  of  study  conduct  NR  NR  NR NR  NR  NR  NR  NR NR
Day  of  mating  conﬁrmation  (GD  0  or  GD  1)  GD  0  GD  0  GD  1  NR  NR  NR  GD  1  GD  0  GD  0
Day  of  cesarean  section  GD  21  GD  18  GD  21  GD  21  GD  30  GD  21  Delivered  Delivered  Delivered
Treatment
Test  Substance  TCE  TCE  TCE  TCE  TCE  TCE  (Trilene)  TCE  TCE  TCE
Source  Dow  Dow  Dow  NR  NR  ICI  Aldrich  Aldrich  Aldrich
Purity  (%)  99.24%  99.24%  99%  NR  NR  NR  NR
>  99% >  99%
Route  of  administration Inhalation  a Inhalation  a Inhalation  a Inhalation  b Inhalation  b Inhalation  a Gavage  Gavage  Gavage
Negative  control  (vehicle) Filtered  room  air Filtered  room  air Filtered  air Air  Air  Ambient  air  Corn  oil  Corn  oil  Corn  oil
Positive  control N  N  N  N  N  N  N  N  N
No.  of  treated  groups 1  1  1  1  1  1  2  2  4
Group  size  (litters/group) 30,  18  26,  12  8–12  (30)  (20)  31–32  (30)  16–21  8–12
Random  assignment  of  test  subjects  to  groups NR  NR  Y  NR  NR  NR  NR  Y  NR
Dose  period  (duration)  GD  6–15  GD  6–15  GD  1–20  GD  1–19  GD  1–24  GD  8–21  GD  1–5,  6–10,  or
11–15
GD  6–19  GD  6–15
Daily  dosing  schedule  7  h/day,
7  days/wk
7  h/day,
7  days/wk
6  h/day,
7  days/wk
6–7  h/day,
7  days/wk
6–7  h/day,
7 days/wk
4  h/day,  days/wk
NR
1x/day  1x/day  1x/day
Maternal  evaluation
In-life  data  (BW,  FC,  WC, and/or  clinobs)  Y  Y  Y  NR  NR  Y  Y  Y  Y
Postmortem  data  (necropsy,  organ  wts,  pathology,  and/or  CL)  Y  Y  Y  Y  Y  Y  Y  N  N
Fetal  evaluation
Implantations  and  resorptions  (early  and  late)  Y  Y  Y  NR  NR  Y  N  N  N
Fetal  weight,  length,  sex  Y  Y  Y  NR  NR  Y  Y  (PND  1)  Y  (PND  1)  Y  (PND  1)
External  fetal  exam  Y  Y  Y  NR  NR  Y  Y  (PND  1)  Y  (PND  1)  Y  (PND  1)
Percent  fetuses  (litters)  evaluated  for  external  ﬁndings  100  (100)  100  (100)  100  (100)  NR  NR  100  (100)  100  (100)  100  (100)  100  (100)
Visceral  examination  Y  Y  Y  NR  Y  c  Y  N  Y  d  Y  d
Percent  fetuses  (litters)  evaluated  for  visceral  ﬁndings  50  (100)  50  (100)  ∼33  (100)  e  NR  NR  100  (100)  NA NR (NR)  NR  (NR)
Fresh  dissection  (in  situ  organ  examination)  N  N  N  NR  NR  Y  N  N  Y  f
Wilson  exam  (Bouins  ﬁxation,  free-hand  sections)  Y  Y  Y  NR  NR  N  N  Y  Y
Fetal  cardiac  examination  methods  NR  NR  NR NR  NR  NR  N  N  N
Fresh  dissection  and  evaluation  NR  NR  NR NR  NR  NR  N  N  N
Free-hand  section  of  decalciﬁed  fetuses  Wilson  Wilson  Wilson  NR  NR  NR  N  Wilson  d  Wilson  d
Preservation  Bouin’s
immersion
Bouin’s
immersion
Bouin’s
immersion
NR  NR  NR  N  Bodian’s
immersion
Bodian’s
immersion
Conﬁrmation  of  ﬁndings  NR  NR  NR NR  NR  NR  N  N  N
Skeletal  examination  Y  Y  Y  NR  NR  Y  N  N  N
Percent  fetuses  (litters)  evaluated  for  skeletal  ﬁndings  50  (100)  50  (100)  ∼33  (100)  e  NR  NR  100  (100)  NA NA NA
Bone  development  Y  Y  Y  NR  NR  Y  N  N  N
Cartilage  development  N  N  N  NR  NR  N  N  N  N
Random  selection  of  fetuses  for  visceral  or  skeletal  evaluation  NR  NR  N  NR  NR  NA  N  N  N
Assessment  of  fetuses  without  knowledge  of  treatment  group  NR  NR  NR NR  NR  NR  N  N  N
This table only includes mammalian studies with prenatal TCE exposures and an evaluation of fetal morphology.
NR  = not reported; NA = not applicable; Y = yes, N = No; DW = drinking water; GD = gestation day; PND = postnatal day; RA = retanoic acid; GLA  = gluteraldehyde.
Test  subject strain: SD = Sprague-Dawley, LE = Long Evans, WIS  = Wistar, NZW = New Zealand White, SW = Swiss Webster.
Test  subject Source: CRL = Charles River Laboratories, Jackson = Jackson Laboratories, Harlan = Harlan Laboratories.
Group sizes are range of actual group size (i.e., no. of dams) on study; numbers in parentheses () indicate target group size.
a  = Whole-body exposure, dynamic air ﬂow, analytical chamber concentrations.
b  = Whole-body exposure, inadequately characterized.
c  = Visceral examination was  NR; however, brain malformations in TCE-treated rabbit fetuses were discussed.
d  = Visceral examination of dead pups only; free-hand (Wilson’s) sectioning of head only.
e  = Four fetuses/litter were assigned to visceral examination and 4 fetuses/litter were assigned to skeletal examination. (33% is an estimate based upon the presumption of 12 fetuses/litter.)
f  = Visceral evaluation of affected (i.e., abnormal) pups only.
Cardiac evaluation references: Staples exam: Stuckhardt and Poppe [82], Staples [80], Wilson [92]; University of AZ exam: Johnson et al. [51], Dawson et al. [20].
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Table  5b
Comparison of Methods Reported for Prenatal Developmental Toxicity Studies with TCE.
Dawson et al. [20] Johnson et al. [51] Fisher et al. [28] Carney et al. [15]
Study Description/Objective
GLP; guideline [G], or research [R] protocol R R R GLP, G
Test  Subjects
Species Rat Rat Rat Rat
Strain  SD SD SD SD
Source (company) Harlan Harlan CRL CRL
Source (location Indianapolis, IN Indianapolis, IN Raleigh, NC Portage, MI
Dates  of study conduct 1989–1990 1989–1995 NR NR
Day  of mating conﬁrmation (GD 0 or GD 1) NR NR GD 0 GD 0
Day  of cesarean section GD 22 GD 22 GD 21 GD 21
Treatment
Test  Substance TCE TCE TCE TCE
Source Aldrich Aldrich Aldrich Dow
Purity (%) NR NR NR 99%
Route  of administration DW DW Gavage Inhalation a
Negative control (vehicle) Tap water Distilled water Soybean oil Ambient air
Positive  control N N RA N
No.  of treated groups 2 4 1 3
Group  size (litters/group) 9–15 9–12 19–25 27
Random assignment of test subjects to groups Y Y Y Y
Dose  period (duration, gestation-only groups) GD 1–22 GD 1–22 GD 6–15 GD 6–20
Daily  dosing schedule Ad libitum, 24 h/day Ad libitum, 24 h/day 1x/day 6 h/day, 7 days/wk
Maternal evaluation
In-life data (BW, FC, WC,  and/or clinobs) Y Y Y Y
Postmortem data (necropsy, organ wts, pathology, and/or CL) Y Y Y Y
Fetal  evaluation
Implantations and resorptions (early and late) Y Y Y Y
Fetal  weight, length, sex Y Y Y Y
External fetal exam Y Y Y Y
Percent fetuses (litters) evaluated for external ﬁndings 100 (100) 100 (100) 100 (100) 100 (100)
Visceral examination Y Y Y Y
Percent fetuses (litters) evaluated for visceral ﬁndings 100 (100) 100 (100) 100 (100) 50 (100)
Fresh dissection (in situ organ examination) Y (heart) Y (heart) Y (heart) Y (viscera)
Wilson  exam (Bouins ﬁxation, free-hand sections) N N N Y (head)
Fetal  cardiac examination methods Y Y Y Y
Fresh  dissection and evaluation UA method UA method UA method Staples exam
Free-hand section of decalciﬁed fetuses N N N N
Preservation GLA ﬂush & immersion GLA ﬂush & immersion formalin immersion NR
Conﬁrmation of ﬁndings Y b Y b NR NR
Skeletal examination NR NR NR Y
Percent fetuses (litters) evaluated for skeletal ﬁndings NR NR NR 50 (100)
Bone  development NR NR NR Y
Cartilage development NR NR NR Y
Random selection of fetuses for visceral or skeletal evaluation NA NA NA NA
Assessment of fetuses without knowledge of treatment group Y Y Y Y
This table only includes mammalian studies with prenatal TCE exposures and an evaluation of fetal morphology.
NR  = not reported; NA = not applicable; Y = yes, N = No; DW = drinking water; GD = gestation day; RA = retanoic acid; GLA = gluteraldehyde; UA = University of Arizona.
Test  subject strain: SD = Sprague-Dawley.
Test subject Source: CRL = Charles River Laboratories; Harlan = Harlan Laboratories.
Group sizes are range of actual group size (i.e., no. of dams) on study; numbers in parentheses () indicate target group size.
a  = Whole-body exposure, dynamic air ﬂow, analytical chamber concentrations.
b  a ped
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o = Unanimous agreement of cardiac diagnoses by study investigators (a pathologist,
as  diagnosed and recorded.
ardiac evaluation references: Staples exam: Stuckhardt and Poppe [82], Staples [8
enetic predisposition and environmental exposures contributing
o the multifactorial etiology [68].
.1.3. Mechanistic data on developmental pathways and
rocesses
Mechanistic mode-of-action data were discussed in the 2011
RIS assessment [87] and provided one line of evidence regarding
he potential for TCE to cause cardiac defects. There was not an
xplicit linkage to the developmental pathways and processes driv-
ng CHD in general or valvulo-septal defects in particular. To expand
pon and reﬁne this discussion, a preliminary conceptual model
ased on an Adverse Outcome Pathway (AOP) framework for CHD
ould be useful. Although such AOP elucidation is beyond the scope
f the present review, data identiﬁed in the systematic literatureiatric cardiologist, and a veterinarian) was required before a positive cardiac ﬁnding
iversity of AZ exam: Johnson et al. [51], Dawson et al. [20].
search and MGI  database search provides motivation for that future
activity. Information upon which a preliminary AOP  construct is
based supports the biological plausibility that TCE exposures dur-
ing development could lead to disruption of key processes in the
development of cardiac valves and septa.
The most commonly reported cardiac defects associated
with gestational exposures to TCE and its metabolites TCA
and DCA in humans, rats, and chickens were valvulo-septal
defects (atrial septal defects [ASDs], muscular and membranous
ventricular septal defects [VSDs]) and pulmonary and aortic steno-
sis [16,29,94,51,49,8,9,20,19,35,57]. In particular, the period of
valvulo-septal morphogenesis deﬁnes a window of TCE vulnerabil-
ity in avian systems; thus an AOP anchored to this dysmorphology
could identify relevant key events and key event relationships fol-
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Table 6
Comparison of cardiac evaluation methods.
Method Reference Description
Wilson Wilson [92] • Immersion ﬁxation of whole fetus in Bouin’s solution
•  Free-hand serial sectioning of fetuses (approximately 2 mm thickness), including sections
through the heart and great vessels
Staples Staples [80]; Stuckhardt and Poppe [82] • Dissection of unﬁxed decapitated or anesthetized fetus
•  Examination of external structure of the heart and great vessels
•  Examination in situ of internal structure of the heart via two cuts:
©  Incision made beginning to the right of the ventral midline surface of the heart at the apex
and extending anteriorly and ventrally into the pulmonary artery (exposing the tricuspid
valve between the right atrium and right ventricle and the 3 cusps of the semilunar valve
of  the pulmonary artery); the interventricular septum examined for defects.
©  Incision made starting to the left of the ventral midline surface at the apex and extending
thorough the left ventricle into the ascending aorta (exposing the bicuspid valve between
the left atrium and left ventricle and the 3 cusps of the semilunar valves of the aorta).
University of AZ Dawson et al. [20]; Johnson et al. [51] • Examination of the great vessels in situ, including pulmonary venous attachment to the left
atrium and cranial and caudal vena caval connections to the right atrium
• Removal of the heart from the thorax; the heart is ﬂushed and then immersion ﬁxed with
2%  gluteraldehyde
• Dissection of unﬁxed fetus
• Examination of external structure of the heart from dorsal and ventral aspects
•  Examination of internal structure of the heart and vessels:
© Right atrial appendage excised to evaluate the atrial septum for defects (left atrial
appendage removed if the atrial septum is not adequately visualized)
© Aorta and pulmonary vessels evaluated for course, caliber, and orientation, then excised at
valve rings
© All remaining atrial tissue removed to expose pulmonary, aortic, tricuspid, and mitral
valves; location of coronary ostium noted; each valve probed for patency, and formation of
each valve leaﬂet examined.
© Incision made ventrally through the tricuspid valve to the apex of the heart. Another
incision made through the pulmonary valve toward the apex of the heart and joining the
cut made through the tricuspid valve. Incision made from each edge of the mitral valve
rd the
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owing exposure to TCE during the vulnerable period. In normal
ardiac development, valvulo-septal morphogenesis is driven by
esenchymal cells in the regions of the atrioventricular canal (AVC)
nd outﬂow tract (OFT) regions. AVC cushions are formed as mes-
nchymal cells are derived from squamosal endothelial cells by
pithelial-mesenchymal transition [EMT], speciﬁcally of endothe-
ial origin [EndMT], and invade and populate the cardiac jelly
atrix. These mesenchymal cells subsequently proliferate and dif-
erentiate to form the AV valves and membranous septum. They
lso contribute to patterning the myocardium via directing vascu-
ar ﬂow. Evidence points to a stepwise EndMT cascade involving
he following key events [46,54,89]:
initiation of EndMT by signal molecules elaborated from myocar-
dial cells into the cardiac jelly;
disassembly of cell–cell junctions between squamosal endothe-
lial cells in the endocardium;
delamination by loss of polarity, cytoskeletal rearrangement, and
breakdown of basal lamina;
invasion of cardiac jelly by newly motile mesenchymal cells;
proliferation of trans-differentiated mesenchyme to ‘cellularize’
and remodel the cardiac jelly;
patterning of the AV myocardium by ﬂow-mediated remodeling
of the looped heart;
differentiation of cardiac valves and membranous septum.
A search of the MGI  database (http://www.informatics.jax.org/)
or abnormalities in cardiac EMT  identiﬁed mouse knockouts with
evelopmental phenotypes similar to those reported for avian
tudies with TCE, implicating the possibility of disruption of the
ollowing genetic signals and responses by TCE exposure dur-
ng cardiac development. Candidate genes implicated pathways apex, and the left ventricular free wall removed (allowing complete
on of the ventricular septum for evaluation of defects).
such as TGF-beta signaling, ephrin signaling, Notch signaling, the
VEGF pathway, and RXR signaling. Potential molecular initiating
events, not yet evaluated experimentally, may involve a cellular
initiation of vascular inﬂammatory signals, perhaps through an
LXR/RXR-mediated effect on cholesterol homeostasis, vulnerabil-
ity to reactive oxygen species (ROS) [91,41,28], or disruption of the
downstream consequences of VEGF signaling [65].
In support of disruption of EndMT being a potential key event
in TCE-induced valvulo-septal defects, embryonic TCE exposure
has been associated with inhibition of cell–cell separation and
mesenchymal formation [10], alterations in mesenchymal cell
migration [60,75] and alterations in endocardial proliferation pat-
terns [24]. In ovo studies have shown that TCE and TCA can alter
cushion formation, cardiac function, and embryo survival [23], and
cushion cellularity can be altered as a function of concentration,
duration, and timing of exposure. The ephrin-EPH system might be
of high relevance to an AOP for TCE-induced valvulo-septal defects.
Loss of Ephrin-A1 in mice, a ligand for class A Eph receptor tyro-
sine kinases, results in thickened aortic and mitral valves. These
embryos display hypercellularity in outﬂow tract endocardial cush-
ions and elevated mesenchymal marker expression, suggesting
that excessive numbers of cells undergo EMT [30]. Ephrin-A1 and
its cognate receptor (EphA3) are expressed in adjacent cells in
the developing endocardial cushions. In contrast to the ligand,
functional inactivation of EphA3 results in hypoplasia of AVC endo-
cardial cushions with fewer migrating mesenchymal cells [81]. As
such, disruption of Ephrin-A1 ligand or EphA3 receptor function
impacts endocardial cushion formation in different ways, poten-
tially leading to hypercellularity or hypocellularity, respectively.
Both effects have been described in in vitro models of TCE-induced
effects on endocardial cushions. Endocardial disruption may have
additional or downstream consequences on the developing heart,
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elated to dysregulation of cellular Ca2+ ﬂuxes and cardiac contrac-
ility [58,66,59,14,76,17] or to alterations in cardiac hemodynamics
72].
.1.4. Weight of evidence (WOE) for hazard
The WOE  (evidence integration) for fetal cardiac defects was
haracterized according to the criteria described in A Framework
or Assessing Health Risk of Environmental Exposures to Children
86], a scheme that is derived from principles of causality assess-
ent developed by Hill [43]. The key components (factors) of
he WOE  analysis were: temporality, strength of association, vari-
bility analysis, uncertainty analysis, qualitative dose-response,
xperimental evidence, reproducibility (consistency), biological
lausibility, alternative or multiple explanations, speciﬁcity, and
oherence (Fig. 1). Independent assessments of the WOE  were
onducted by reviewers, and a group consensus of the evidence
upporting stronger and weaker weights of association for each key
actor was derived. The evidence supporting stronger and weaker
eight of association for each key factor is presented in Table 7.
Despite the recognized uncertainties and limitations in the
CE database, the evidence supports a conclusion that TCE has
he potential to cause cardiac defects in humans when exposure
ccurs at sufﬁcient doses during a sensitive period of fetal devel-
pment. This conclusion is warranted by the data that demonstrate
r suggest a potential hazard to cardiac development, includ-
ng epidemiological studies, developmental toxicology studies in
odents with TCE and its metabolites (DCA and TCA), avian in
vo studies, in vitro assays, and mechanistic data that form the
asis of a preliminary conceptual model of an AOP for valvulo-
eptal defects resulting from TCE exposures. Limitations within
he database that increase the uncertainties regarding this conclu-
ion are acknowledged. These limitations are described in detail
bove. The epidemiological studies provide evidence of associa-
ions between TCE, or TCE and other chlorinated solvents, and
ardiac defects, but these studies have limitations related mainly
o exposure measurement error and lower statistical power due to
he rarity of cardiac defects. The rodent developmental toxicology
tudies conducted by Dawson et al. [20], Johnson et al. [51], and
ohnson et al. [49] that reported cardiac defects resulting from TCE
and metabolite) drinking water exposures have study design and
eporting limitations. Additionally, two good quality (GLP) inhala-
ion and gavage rodent studies conducted in other laboratories,
arney et al. [15] and Fisher et al. [28], respectively, have not
etected cardiac defects.
In accordance with the Guidelines for Developmental Toxicity
isk Assessment [85], the database is considered to be adequate to
upport categorization of the health-related database for hazard
nd dose-response, with the determination that there is “Sufﬁ-
ient Experimental Animal Evidence” and “Limited Human Data”
or developmental cardiac toxicity. This category “includes data
rom experimental animal studies and/or limited human data that
rovide convincing evidence for the scientiﬁc community to judge
hat a potential for developmental toxicity exists.” The minimum
vidence that would be necessary to determine whether there is or
s not sufﬁcient evidence of developmental toxicity is the existence
f appropriate, well-conducted animal studies. The overall TCE
atabase met  this criterion, although limitations and uncertainties
n the primary study used in dose response [51] are acknowledged.
.2. Dose-response assessment for developmental cardiac defects
Given the hazard conclusion that (despite uncertainties and
imitation in the database) TCE has the potential to cause cardiac
efects in humans when exposure occurs at sufﬁcient doses dur-
ng a sensitive period of fetal development, the next critical issue
ddressed by this update is the dose-response assessment.icology 65 (2016) 321–358 345
3.2.1. Suitability of Johnson et al. [51] study for deriving a point
of departure for a reference value
The Johnson et al. [51] study is the only available study poten-
tially useable for dose-response analysis of fetal cardiac defects.
On the whole, the Johnson et al. [51] study is considered suit-
able for use in deriving a POD for the following reasons. The study
has an appropriate design. It was  conducted by a relevant route
of exposure (drinking water), covered the entire period of gesta-
tion which subsumes the developmental window for the initiation
of cardiac defects, and tested multiple exposure levels. Further
support was  derived from the ﬁnding of a robust, statistically sig-
niﬁcant dose-response relationship. Additionally, this judgement
took into consideration the strengths and limitations of the study
and uncertainties identiﬁed in the WOE  analysis.
The study was conducted over a period of 6 years, with exposed
animals and their concurrent controls distributed across time. This
design is not problematic per se; clinical trials and epidemiological
studies are frequently conducted similarly, with staggered entry
of subjects [31,69]. An important consideration to address is the
potential for increased variability among litters owing to temporal
drift and other possible factors.
Overdispersion, or greater variation among litters than is
expected based on within-litter variation among offspring, can be
dealt with by a standard method for clustered data [77,33,55,32,67].
This method deals effectively with between-litter variation from
all sources, assuming that within-litter variation (conditional on
the litter-mean) is approximately binomial. This method was
applied for signiﬁcance tests and dose-response analyses (dis-
cussed below).
Another concern about the study design is that the two high-
est exposure levels and their associated controls were observed in
1989–93, and the two lowest exposures and their controls were
observed during 1993–1995 (Table 8; [53,52]). This raises a ques-
tion whether temporal change rather than exposures can account
for the observed responses. We  also note that the two highest TCE
doses and their controls, reported originally in Dawson et al. [20],
used tap water as a vehicle and drinking water source. Hypothet-
ically, if teratogens in tapwater did increase cardiac defects, that
would likely increase the control response and perhaps impede the
ability to observe a signiﬁcant increase.
Employing all of the data, there is a highly signiﬁcant (P < 0.001)
increasing dose-response trend (Fig. 6) based on a Cochran-
Armitage trend test after adjusting for overdispersion. The trend
is also signiﬁcant (P < 0.04) when the highest dose is dropped. The
temporal disjunction between the middle and high dose groups
prompts further examination. There is no signiﬁcant trend for the
two low-dose groups and their controls. When the two high dose
groups and related controls (Table 8) were considered separately,
a signiﬁcant trend (P < 0.03) was found.
Conﬁdence that data from Johnson et al. [51] represent a real
response is supported by the increasing trend in response (Fig. 6),
and the observations of higher percentages of cardiac malforma-
tions elicited by higher doses (500 mg/kg-day and higher) in studies
of rats exposed to TCE metabolites, TCA and DCA [27,79,78]. The
highest dose in the Johnson et al. [51] study lies at the lower end
of doses that elicited substantial responses in these other studies.
Thus, a hypothesis that the Johnson data represent a false positive
or an anomalous dose-response pattern seems implausible, based
on trend tests and comparison with studies that used higher doses.
3.2.2. Dose-response modeling of the data from Johnson et al. [51]
Dose-response modeling of the cardiac malformation data fromJohnson et al. [51] was conducted using the nested log-logistic and
other BMDS models (http://www.epa.gov/ncea/bmds/) and a BMR
of 0.01 (1%) extra risk, the BMR  level that was used in the EPA 2011
TCE assessment [87].
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Table 7
WOE  Evaluation of the Potential for Development Exposures to TCE to Result in Cardiac Defects.
Key Factora,b Type of evidence considered Data Evidence for stronger
weight of association
Evidence for weaker
weight of association
Comments
or Null Evidence
Temporality Timing of exposures and response Tox Studies in various species in which TCE (or
metabolites DCA or TCA) were
administered during a sensitive period of
in utero cardiac development resulted in
morphological and/or functional
alterations.
• Drinking water administration of TCE to
rats on GD 1–22 resulted in a statistically
signiﬁcant treatment-related increase in
the incidence of cardiac defects [51,20].
•  Drinking water administration of TCA
(the TCE oxidative metabolite) to rats on
GD 1–22 resulted in a statistically
signiﬁcant treatment-related increase in
the incidence of cardiac defects [49].
Gavage administration of TCE
metabolites (DCA and TCA) on GD 6–15
[78] or of DCA during discrete windows
of  time within GD 6–15 [27] resulted in
treatment-related increases in the
incidences of cardiac defects.
• Avian in ovo studies that administered
TCE or TCA during the period of
valvuloseptal morphogenesis (e.g., HH
15–20) resulted in altered cardiac
morphology and/or function [72,23].
•  A study of DCA exposure to zebra ﬁsh
[41] demonstrated evidence of a
disruption in cardiac development
(pericardial edema and altered heart
rate).
•  Mouse whole embryo culture studies of
DCA and TCA administered at the period
of 3–6 somites detected cardiac defects
[44]; a chicken whole embryo culture
study of TCE administered at HH 13–14
detected alterations in AV cushion [60].
•  Avian atrioventricular canal cell culture
(HH 16) study found evidence of
inhibited endothelial cell separation and
early events of mesenchymal cell
formation in the heart following TCE
exposures [10].
Some in vivo or in vitro studies rodent studies
in  which TCE (or metabolites DCA or TCA) was
administered during a sensitive period of in
utero cardiac development resulted in no
morphological alterations.
• Gavage administration of TCE or metabolites
(DCA and TCA) to rats on GD 6–15 did not
result in treatment-related cardiac defects
[28].
• Inhalation exposures of TCE to rats on GD
6–20 [15] or to rats and mice on GD 6–15
[74] did not result in treatment-related
cardiac defects.
• NE
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Exposure occurs before outcomes onset Epi • Four cohort or case-control studies
consider temporality [71,29,94,35].
Three studies observed an association
between the TCE exposure surrogate
and major cardiac defects [29,94,35]. An
association with conotruncal defects,
speciﬁcally, was  observed in Forand
et al. [29].
• Temporality was not considered in Bove
[8]/Bove et al. [9], Goldberg et al. [35], or
Lagakos et al. [56].
• The small numbers of conotruncal heart
defects in Ruckart et al. [71] precluded
any analysis of this endpoint and TCE
exposure.
Strength  of association Study quality, including study strengths
and limitations
Tox • For Johnson et al. [51], Dawson et al.
[20], and Johnson et al. [49], all of which
detected cardiac malformations, study
quality strengths include randomized
assignment to test group, detailed
description of fetal cardiac dissection
and evaluation procedures, evaluation of
fetal hearts without knowledge of
treatment group, and conﬁrmation of all
cardiac defects by consensus of 3
experts. Statistical analysis of data from
this study was appropriately conducted
by EPA statisticians using individual
fetal and litter data that were provided
by the study author.
• The power of detection in the Johnson
et  al. [51] study was enhanced by the
use of historical controls that did not
demonstrate a temporal shift in cardiac
defects. A signiﬁcant dose related trend
in cardiac defects was  observed even
without large group sizes.
• A strong association of exposure to
response was  observed at high dose
levels in multiple studies that identiﬁed
cardiac defects. In Johnson et al. [51]
there was a highly signiﬁcant positive
trend for cardiac defects.
• Potential confounding factors exist in
studies that did not identify cardiac
defects (e.g., different routes of
exposure, the use of different rodent
strains or suppliers across studies, and
the use of soybean oil as a vehicle in
Fisher et al. [28].
• For Johnson et al. [51] major study quality
limitations include the use of data pooled
from separate study cohorts conducted over
an approximately 6-year period, the use of
tap water as the vehicle for some of control
and treated groups (as reported by Dawson
et al. [20] with no characterization of
possible contaminants and incomplete
reporting of study methods and results.
• While Dawson et al. [20] indicated that
levels of TCE in dose formulations were
tested by gas chromatography, the analytical
ﬁndings were not reported. Johnson et al.
[51] did not report whether dose
formulations were analyzed. Further, levels
of TCE were not assessed in the vehicle
control water; therefore, it is plausible that
TCE contaminated the water and that doses
were actually higher than measured.
• The Dawson et al. [20] and Johnson et al.
[51] studies estimated doses based on the
average water consumption. This method
does not provide precise information to
calculate TCE dose because variability in
drinking water consumption among dams is
not characterized.
•  The dose selection for Johnson et al. [51]
resulted in a NOAEL that is approximately
700-fold lower than the next highest dose.
• Some studies that did not identify
treatment-related cardiac defects following
developmental exposures to TCE, e.g.,
Carney et al. [15],  Fisher et al. [28], and
Schwetz et al. [74], were well-conducted
and adequately-reported GLP and/or
guideline studies with no substantive
limitations identiﬁed.
• One study [28] attempted to replicate the
methods used in the Johnson et al. [51]
study, utilizing the same fetal cardiac
dissection and evaluation techniques, and
including one of the Johnson et al. [51] study
authors in the assessment team, yet found
no treatment-related cardiac defects.
• Some studies that reported no cardiac
defects following TCE gestational
exposures [61,62,42,39] or avian in ovo
studies [12,26] did not indicate that
detailed evaluation of fetal hearts was
conducted.
•  A rat whole embryo culture study of TCE
administered at the period of 4–7
somites detected no cardiac defects in a
study by [73]; however, the study
methods indicate that there was no
evaluation of the embryonic heart.
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Table 7 (Continued)
Key Factora,b Type of evidence considered Data Evidence for stronger
weight of association
Evidence for weaker
weight of association
Comments
or Null Evidence
Magnitude of the effect measure Epi • Increased risk estimates between all or
major cardiac defects ranged from 1.24
(95% CI: 0.75, 1.94) to 2.40 (95% CI: 1.27,
3.62) observed in 3 studies [29,9,35].
Stronger associations, observed with the
TCE exposure surrogate for conotruncal
defects and ventricular septal defects
than for major cardiac defects, a broader
category [29,9]. A fourth study observed
an increased risk estimate of 6.2 (95% CI:
2.6, 14.5) for cardiac defects in infants of
mothers aged ≥38 years and maternal
residence within 1.32 miles from at least
one TCE emissions source [94].
• No association in Yauck et al. [94] in
mothers <38 years of age and maternal
residence within 1.32 miles from at least
one TCE emissions source nor in Lagakos
et al. [56], which does not observe an
association with cardiac defects. Alternative
reasons such as lower statistical power may
explain these observations.
• NE
Variability analysis Sources of within- and cross-study
variability that contribute to uncertainty
Tox • Johnson et al. [51] test subject source,
husbandry, and randomization
procedures were consistent across all
cohorts, i.e., including Dawson et al. [20]
and metabolite studies Johnson et al.
[51]. Fetal cardiac evaluation
methodology, which included evaluation
without knowledge of treatment group
and conﬁrmation of all cardiac
anomalies by 3 expert scientists, was
also consistently applied across cohorts
and studies from the UA laboratory. This
had the result of reducing intra- and
inter-study variability in the assessment.
•  Johnson et al. [51] reported that cardiac
defect incidences were consistent across
all  control cohorts (55 litters over
approximately 6 years). An EPA review
of the available control data did not
observe unusual heterogeneity in
prevalence of malformations.
• Studies that reported cardiac defects
following administration of metabolites
(DCA and TCA) used randomized
assignment of maternal animals to test
group, thus reducing intra-study
variability.
•  Although Dawson et al. [20] and Johnson
et  al. [51] identiﬁed cardiac defects
following exposures to TCE during
development, Carney et al. [15], Fisher
et al. [28], and Schwetz et al. Schwetz
et al. (2006) did not ﬁnd
treatment-related cardiac abnormalities.
This may be the result of differences in
the study design and assessment
methods. This includes such aspects as
animal strain, age, source, exposure
route and vehicle, duration of exposure,
and cardiac evaluation methods.
• The Johnson et al. [51] study reported data
from several cohorts of animals, which were
on  study over a period of approximately 6
years. The data included control cohorts,
some of which were concurrent and some
that were non-concurrent to the TCE-treated
groups [53,52]. Data that deﬁnitively link
the individual control litter response data
with each particular cohort are no longer
available for independent examination.
• Different study outcomes were observed in
studies that had many similarities in study
design and conduct, i.e., Dawson et al. [20]
and Johnson et al. [51] identiﬁed exposure
related cardiac defects while Fisher et al.
[28] did not. In the Fisher et al. [28] study,
care was taken to ensure that the same
cardiac evaluation methods were used as in
the Dawson et al. [20] and Johnson et al. [51]
studies, including fetal evaluation with
knowledge of treatment group, and one of
the study authors of Johnson et al. [51]
participated in the fetal examination.
•  The use of soy bean oil in the Fisher et al.
[28] study vs. water vehicle and control for
Johnson et al. [51] and Dawson et al. [20]
studies.
• The Johnson et al. [51] and Dawson et al.
[20] studies did not calculate variability in
TCE dose by measuring individual dam
water consumption.
• Based upon the toxicokinetic proﬁle of
TCE [87], it is considered unlikely that
toxicokinetic factors contributed
signiﬁcantly to differences in response
across study protocols.
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Sources of within- and cross-study
variability that contribute to uncertainty
Epi • NE (not considered in Hill analysis) • NE (not considered in Hill analysis) • Studies examined different populations,
exposure levels, gradients, and media.
Additionally, different sets of strengths
and uncertainties in this set of studies
would contribute to observed
cross-study variability.
Uncertainty analysis Missing information or data gaps, within
and across studies
Tox • For the studies conducted by the UA
laboratory [51,20] that identiﬁed cardiac
defects following exposures to TCE, DCA,
or TCA, detailed descriptions of
evaluation methods for assessment of
cardiovascular effects were provided.
•  Individual fetal and litter cardiac
ﬁndings data, as well as detailed
information on study conduct and fetal
evaluation methods, were provided to
the EPA for Johnson et al. [51] and
Dawson et al. [20].
• The publications for studies conducted by
the UA laboratory that identiﬁed cardiac
defects following exposures to TCE, DCA, or
TCA [51,49,20] did not report essential study
details, and generally did not include
summaries of maternal data or fetal data for
endpoints other than cardiac defects.
• For well-conducted studies that did not
detect cardiac defects following
developmental exposures to TCE or
metabolites [15,28] adequate descriptions of
study methodology and summary data for
maternal and fetal ﬁndings were reported.
• Mechanistic data for alterations in cardiac
development are limited and do not identify
initiating events for the putative AOP.
• NE
Missing information or data gaps, within
and across studies
Epi • NE (not considered in Hill [43] analysis) • NE (not considered in Hill analysis) • NE
Qualitative
dose-response
Association between exposure/dose and
degree of effect
Tox • Alterations in cardiac development were
observed in multiple studies at high
dose levels following TCE, DCA, or TCA
exposures [51,49,20,79,78].
• The incidence of cardiovascular effects
increased as a function of dose in
Johnson et al. [51].
• An association between exposure to TCE
(or DCA or TCA) and alterations in
cardiac development was reported in
various animal models, i.e., LE and SD
rats, CD-1 mice, chicken embryos, and
zebra ﬁsh [23,24,91,41,51,20,79,78].
• A BMDL for Johnson et al. [51] was
derived by EPA statisticians from
individual cardiac defect data provided
to EPA. Litter contribution to the
outcome of interest was incorporated in
the analysis. A signiﬁcant dose-response
trend was  identiﬁed, whether or not the
high dose value was  included in the
analysis.
• The dose response for cardiac defects
identiﬁed by Johnson et al. [51] could only
be  ﬁt to a model with elimination of the high
dose data from the analysis. The lowest dose
tested had a zero response for cardiac
defects, below the historical control
incidence. The doses tested were spaced
over several orders of magnitude, with wide
gaps.
• Carney et al. [15] was the only other study in
the database that evaluated developmental
effects of TCE over multiple dose levels. In
that study, no fetal toxicity and minimal
maternal toxicity was reported.
• TCE doses tested in Johnson et al. [51]
and Dawson et al. [20] (drinking water):
2.5 ppb, 250 ppb, 1.5 ppm, or 1100 ppm
(0,  0.00045, 0.048, 0.218, or
129 mg/kg-day)
• TCE doses tested in Fisher et al. [28]
(gavage): 500 mg/kg-day
• TCE doses tested in Carney et al. [15]
(inhalation): 50, 150, or 600 ppm (268.5,
805.5, or 3222 mg/m3)
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Key Factora,b Type of evidence considered Data Evidence for stronger
weight of association
Evidence for weaker
weight of association
Comments
or Null Evidence
Exposure-response gradient: Association
between exposure/dose and degree of
effect
Epi • NE • Goldberg et al. [35] and Lagakos et al. [56]
examined exposure-response; none
observed.
• NE
Experimental evidence Hypothesis testing: manipulation of
exposure scenario with resulting
alterations in response
Tox • A study by [27] administered the
metabolite DCA to rats on varied days of
gestation and identiﬁed critical
windows of exposure for eliciting
cardiac developmental defects.
•  No statistically signiﬁcant increases in
congenital heart defects were observed
in  groups of rats that were exposed to
TCE prior to pregnancy only [20].
•  Drake et al. [24] demonstrated that
cardiac defects did not occur in chick
embryos exposed to TCE and TCA during
the period of cardiac speciﬁcation
(approximately GD 6 in rats) rather than
the period of valvuloseptal
morphogenesis.
• Studies in rodents that administered TCE via
drinking water detected an increase in
fetuses with cardiac defects [51,20]; studies
that administered TCE via other routes
(gavage and inhalation) were negative for
this response [15,28,74].
•  In a whole embryo culture (WEC) study of
DCA and TCA [44], that identiﬁed cardiac
defects, the acid nature of DCA and TCA may
have impacted dysmorphogenesis.
• Studies that manipulated the gestational
exposure period were not conducted
with TCE.
Association not observed once exposure
ceases
Epi • NE • No differences between observed and
expected numbers of cardiac defect cases
once wells were closed in contaminated area
[35].
• NE
Reproducibility
[Consistency]
Reproducibility: Corroboration across
studies, labs, routes of exposure, species,
etc.
Tox • Studies that administered TCE in
drinking water to rats on GD 1–22 were
conducted over a period of
approximately 6 years by researchers at
the same academic facility (UA, Tucson)
used the same cardiac evaluation
methods and identiﬁed treatment and
dose-related cardiac malformations
[51,49,20]. A preliminary screening
study that utilized intrauterine
administration of TCE also detected
cardiac defects [20]. The types of cardiac
malformations observed were similar
across study cohorts and treatment
groups throughout the duration of the
research program.
• Studies on TCE metabolites (TCA and
TCA) conducted in other laboratories
[27,79,78] identiﬁed cardiac defects
similar to those observed in the UA
studies.
•  Cardiac septal anomalies were observed
in avian in ovo studies [72,23], and in
WEC  assays [60,44] with TCE and/or
metabolite exposures. Zebraﬁsh studies
also demonstrated evidence of
alterations in cardiac development
[91,41].
• Studies conducted in other laboratories than
UA and that administered TCE by gavage or
inhalation [15,28,74] did not identify
statistically signiﬁcant increases in cardiac
defects. Fisher et al. [28] used the same
cardiac evaluation methods as the UA lab.
•  Studies that did not identify cardiac
defects with TCE and/or metabolite
exposures [15,28,74] did not replicate all
aspects of the Johnson et al. [51] study,
even though Fisher et al. [28] used the
same cardiac evaluation techniques as
[51] and Dawson et al. [20], and
therefore provide only limited evidence
of  lack of reproducibility.
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Consistency: Association observed in
different populations, places, time and
circumstances.
Epi • Association between cardiac defects and
TCE exposure surrogate observed in four
studies. These studies were of different
populations living in different states
(NY, NJ) and covered slightly different
time periods (1983–2000, 1985–1988)
[29,8,9]. Two other studies of weaker
designs were of different populations
and carried out in two different
locations in the United States, and
provide supporting evidence [94,35].
• Lagakos et al. [56] compared a pregnancy
receiving contaminated residential well
water to a pregnancy not receiving
residential water from contaminated wells
and does not observed an association
between cardiac defects and contaminated
drinking water.
• NE
Biological plausibility Observed outcome can be attributed to
toxic insult given the known science
Tox • Avian in ovo studies and atrioventricular
cell culture studies support the
biological plausibility of effects of TCE on
cardiac development, given that early
chick heart development is similar to
mammalian (including human),
particularly regarding the role of the
cardiac cushion in septation [63].
• Preliminary exploration of a possible
adverse outcome pathway (AOP) has
resulted in a reasonable conceptual
model for TCE-induced congenital heart
defects. In this construct, the vulnerable
period is deﬁned by endocardial
morphogenesis.
Endothelial–mesenchyme transition
(EMT) is disrupted in the area of the
atrioventricular canal, leading to septal
defects. Studies in knockout mice have
suggested the possible disruption of
genetic signals and response by TCE
exposure during cardiac development.
Candidate genes have implicated
pathways such as TGF-beta, ephrins,
Notch signaling, VEGF pathway, and RXR
signaling. Potential molecular initiating
events may  involve a cellular initiation
of vascular inﬂammatory signals,
perhaps through an LXR/RXR-mediated
effect on cholesterol homeostasis,
vulnerability to reactive oxygen species
or disruption of the downstream
consequences of VEGF signaling.
• A deﬁnitive AOP for TCE-induced cardiac
defects, including a putative initiating event,
has not yet been characterized. Additional
mechanistic data are needed to support the
hypothesized AOP.
• There are insufﬁcient mechanistic data to
characterize additional potential MOAs
other than that hypothesized in the AOP
construct.
• It is possible that multiple modes of
action are involved in alterations to
cardiac development.
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Key Factora,b Type of evidence considered Data Evidence for stronger
weight of association
Evidence for weaker
weight of association
Comments
or Null Evidence
Observed association plausible given the
known science
Epi • NE • NE • In vitro and in vivo animal studies report
cardiac defects with TCE and
TCE-metabolite exposure.
Alternative or multiple
explanations
Other possible explanations for observed
outcome after the exposure of interest
Tox • Given the presumed contribution of
both environmental exposures and
genetic predisposition in human
congenital heart disease [68], it is
possible that the test subjects used in
the Johnson et al. [51] study and others
conducted in that laboratory may have
been particularly susceptible to
alterations in cardiac development.
• Other contributing factors or
confounding factors were not
speciﬁcally identiﬁed in the evaluated
in-vivo studies.
•  It is possible that the absence of
treatment-related cardiac defects in
well-conducted TCE studies [15,28] or
metabolite studies [28] was due to
confounding variables such as
differences in strain/source of animal
model, route of exposure, toxicokinetics,
vehicle [e.g., soybean oil in Fisher et al.
[28]], or differences in cardiac
evaluation methods.
•  It is unlikely that the cardiac defects
observed by Johnson et al. [51] were an
artifact of the evaluation procedures
used, since a study by Fisher et al. [28],
using the same fetal cardiac evaluation
procedures, did not identify an
association between TCE exposure and
the incidence of cardiac defects.
• There is a possibility that cardiac defects
detected in the Dawson et al. [20] study
were associated in part with the use of tap
water as a control vehicle (i.e., possible
presence of contaminants).
• NE
Other  possible explanations for observed
outcome after the exposure of interest (not
considered in Hill analysis)
Epi • Potential maternal risk factors were
adjusted in statistical analysis in Forand
et al. [29] and Yauck et al. [94] or were
not found in statistical analyses to
inﬂuence observed association by ±15%
[8,9].
• Potential for confounding from another
exposure given the poor exposure deﬁnition
in Yauck et al. [94]. The positive association
in  Goldberg et al. [35] may result from likely
selection biases in controls.
• NE
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Speciﬁcity Single cause and effect relationship resulting
from exposure to test substance
Tox • Cardiac defects in rats appear to be attributable
to direct chemical exposure to TCE or
metabolites (DCA or TCA) and are unlikely to be
the result of secondary effect of maternal
toxicity. Johnson et al. [51] reported that TCE
exposure via drinking water to pregnant rats did
not  result in maternal toxicity. Carney et al. [15]
reported minimal decreases in body weight gain
in dams, with no adverse fetal outcomes. In
fetuses, there was no indication of TCE-related
fetal weight deﬁcits, external or skeletal
anomalies, or of soft tissue alterations other
than cardiac defects in Johnson et al. [51], nor in
any other study.
• The majority of the cardiac malformations
following TCE exposures to rats [20] or chicks
[72,23] during sensitive periods of cardiac
development were ventricular septal defects,
valve defects, or outﬂow tract abnormalities.
Mechanistic data suggest a common etiology
(disruption of the cardiac cushion formation) for
the observed cardiac defects [10].
• Studies conducted in other laboratories than
UA and that administered TCE by gavage or
inhalation [15,28,74] did not identify cardiac
defects. Fisher et al. [28] used the same
cardiac evaluation methods as the UA lab.
• The cardiac defects detected in the Dawson
et al. [20] study might have been related to
the use of tap water as a vehicle (i.e.,
possible contaminants).
NE
Single cause and effect relationship resulting
from exposure to test substance
Epi • NE • Speciﬁcity not as critical compared to other
Hill aspects since outcomes may have
several risk factors. Maternal risk factors,
speciﬁcally chemical risk factors, associated
with cardiac defects in infants have not been
well studied.
• NE
Coherence Summary: Extent to which data are similar in
outcome and exposure across database
Tox • Multiple studies were conducted at UA
[51,49,20], in which rats were administered TCE
or  metabolites DCA or TCA in drinking water on
GD 1–22 and for which study design and cardiac
evaluation methodologies were consistent. The
outcomes of these studies (detection of cardiac
defects, particularly septal defects, valve
abnormalities, and outﬂow tract anomalies) are
consistent across these studies. Additionally,
these outcomes are supported by the results of
avian in ovo and in vitro studies, studies with
TCE metabolites (DCA and TCA) in rodents,
in  vitro whole embryo culture studies, and
mechanistic data.
• Developmental toxicity studies with TCE
that were conducted in other laboratories
[15,28,74] administered TCE to rats of other
strains or sources, using different routes of
exposure (inhalation or gavage),
administered on different days of gestation
(i.e., not including GD 1–6) than the UA
studies and did not identify cardiac defects.
No other study in the TCE database reported
cardiac defects at the low dose levels
reported by Johnson et al. [51].
• NE
Cause  and effect interpretation should not
conﬂict with the generally known facts of the
natural history and biology of the disease
Epi • Associations in epidemiologic studies of cardiac
defects and maternal occupational exposure to
degreasing solvents or to organic solvents
[34,93,83,84].
• NE • NE
NE = No relevant evidence.
HH = Hamburger-Hamilton stages of chick development [37].
UA = University of Arizona.
Tox = Animal toxicology studies; Epi = Epidemiological studies.
Key Factor References.
a U.S. EPA [86].
b Hill [43].
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Table 8
Data analysis of cardiac abnormalities reported by Johnson et al. [51].
Conc. in drinking water, ppm 0 0 0 0.0025 0.250 1.5 1100
Dose, mg/kg-d 0 0 0 0.00045 0.048 0.218 129
Internal dose metrica 0 0 0 0.00031 0.033 0.15 88
Dates  1989–93 1993–95 all 1994–95 1994–95 1989–90 1989–90
N  (litters)b 20 35 55 12 9 13 9
N  (fetuses)b 232 374 606 144 110 181 105
N  (fetuses with cardiac defect)b 7 6 13 0 5 9 11
p  (fetuses with cardiac defect) 0.0302 0.0160 0.0215 0 0.0455 0.0497 0.1048
a Total Oxidative Metabolism per unit (body weight)3/4; units are mg/wk-kg3/4.
b For the purpose of this analysis, the control litters (fetuses) were designated as belon
control  animals assigned to study, the incidences of cardiac malformations reported, and
Johnson (2008); Paula Johnson, personal communication.
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Fig. 6. Percent of Offspring with Cardiac Defects [51]. The dose is on log scale. The
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logistic model (BMDL05 0.108 mg/kg-day; BMD05 0.337) [87] is
about 5-fold higher than the 2011 BMDL01.
• Model-averaged BMDL01 or BMDL05 for dichotomous mod-
els (using a Rao-Scott transformation to adjust for intra-litterThe nested dose-response model accounts for overdispersion
sing a beta-binomial model [88]. To conﬁrm that approach, we
lso applied a suite of models for dichotomous binomial data after
djusting the data for clustering, using an estimated design effect
f 1.53 [77,33,55,67].
Given the uncertainties in the dose-response analysis related to
he nature of the data, the conﬁdence in the POD based on Johnson
t al. [51] has limitations. Overall, however, the POD derived in the
011 TCE assessment [87], which used an approach consistent with
tandard U.S. EPA dose-response practices, remains a reasonable
hoice.
Several sources of uncertainty related to modeling assumptions
ere examined:
1) Do the data have a plateau at less than 100% response? The
evidence is equivocal and does not permit a clear answer. Con-
sidering the conﬁdence intervals for responses in Fig. 6, it is not
clear whether the response reaches a plateau or increases more
gradually. A number of National Toxicology Program (NTP)
studies of developmental toxicity also have a low but signiﬁcant
maximum response, although they differ in apparent patternging to the 1989-93 or 1993-95 cohorts based upon an analysis of the numbers of
 individual animal identiﬁcation numbers Dawson et al. [20]; Johnson [51,52,48];
of response.3 A model with a plateau is plausible, but would
not substantially change the general conclusion and results.
(We  used the dichotomous-Hill model in BMDS, which allows
a plateau to be estimated.)
(2) Is it better to drop or retain the high dose? For the 2011 TCE
assessment [87], the high dose was  dropped on the strength
of an examination of residuals at the low doses for the nested
model. The decision to drop the high dose is conﬁrmed in
this re-examination, using non-nested dichotomous models
(adjusted for intralitter correlation using estimated design
effects [33]). Dropping the high dose leads to higher model
goodness of ﬁt and better ﬁt in the region of the BMD01 and
BMD05.
(3) Are there sufﬁcient data in the low-dose region and near the
BMD01 to permit reliable inference about the dose-response
curve shape (which inﬂuences the BMD  and BMDL)? BMD  infer-
ence at the 1% extra-risk level is highly uncertain, because BMD
and BMDL values vary by several orders of magnitude depend-
ing on the modeling assumptions. This is attributed in part to
the lack of monotonicity at the lowest dose and the apparent
supralinearity of the overall exposure-response relationship.
Additional doses would be required to better specify the curve
shape in the low-dose region. More reliable inference can be
made for higher BMRs.
3.2.3. Uncertainty in the point of departure (POD)
There is substantial model and parameter uncertainty at the 1%
level of extra risk, although 1% is the appropriate BMR  based on
severity of the effect (i.e., cardiac malformations). These uncertain-
ties can be attributed primarily to having too few data points in the
low-dose range, where more data would be required to adequately
characterize the dose-response shape. Uncertainty decreases for
higher BMR  levels (5% and 10% extra risk), although 10% exceeds
the range of the data for some models.
• The BMDL01 0.0207 mg/kg-day (BMD01 0.0646) for the nested
log-logistic model selected in the 2011 TCE assessment (with
slope constrained and without the high dose group) [87] pro-
vides a compromise value from the range of BMDLs derived from
the variety of models examined.
• With a 5% BMR  (i.e., 5-fold greater), the BMDL for the nested log-3 These NTP studies have a signiﬁcant increase in malformations and
maximum response less than 10%: TER86091, mice, MeDOPA; TER84054,
rabbits, Carbon disulphide; TER82079, rats, Gentian Violet; TER84063, rats,
DEHP; TER84111, mice, theophylline. http://tools.niehs.nih.gov/ntp tox/index.
cfm?fuseaction=ntpsearch.allchemicalsforstudy&searchterm=Developmental.
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correlation; [33]) with the high dose dropped to achieve bet-
ter ﬁt in the low-dose range yielded the following values:
BMD01 0.0809 mg/kg-day and BMDL01 0.0225 mg/kg-day, BMD05
0.282 mg/kg-day and BMDL05 0.178 mg/kg-day. This option
yields results similar to that of the modeling approach used in
the 2011 TCE assessment [87].
The LOAEL/NOAEL approach, although there is also uncertainty
about deﬁning a POD with this approach, uses either the sec-
ond highest dose (0.218 mg/kg-day) or the next lower dose
(0.048 mg/kg-day) as a POD. These are biologically plausible as
LOAELs because the apparent extra risk values calculated from
the observed responses of 2.9% and 2.5%, respectively, exceed 1%,
the level identiﬁed as a suitable BMR.
In summary, additional dose-response analyses were performed
o characterize the uncertainty in the POD. Alternative PODs were
erived based on use of alternative models, alternative BMR  levels,
r alternative procedures (such as a LOAEL/NOAEL approach), each
ith different strengths and limitations. These alternatives were
ithin about an order of magnitude of the POD derived in the 2011
CE assessment [87].
Overall, taking into account the Johnson et al. [51] study design,
trengths and limitations, and uncertainties in the WOE, and in
pite of any reservations based upon considerations pertaining to
onﬁdence in the dose response, a majority of the expert partici-
ants in this update project agreed that the Johnson et al. [51] study
as suitable for use in deriving a POD. The majority of the partici-
ants agreed that the results of the present analysis are consistent
ith and further support the dose-response conclusions of the 2011
RIS TCE assessment [87].
. Discussion/conclusions
This updated systematic review and analysis was  conducted to
ddress the potential for exposure to TCE and its metabolites dur-
ng critical windows of development to result in cardiac defects.
he review developed: (1) an updated characterization of the avail-
ble data and uncertainties in the TCE database for cardiac defects,
2) an expanded consideration of the mechanistic database that
ay  support future research to develop an AOP for cardiac defects
esulting from TCE exposures, (3) documentation of data and WOE
valuations (evidence integration) for hazard, and (4) an extended
haracterization of the dose-response modeling.
.1. Updated characterization of available data and uncertainties
One of the goals of this review was to identify any new data (i.e.,
ostdating the last literature search performed for the EPA 2011
CE document [87]) that address cardiac malformations associated
ith exposures to TCE, DCA, and TCA. A total of 1769 unique cita-
ions were identiﬁed and screened for relevance. Of these, only two
dditional epidemiological studies and two mechanistic studies
et  the established inclusion criteria. We  found no animal toxicol-
gy studies (in vivo, in vitro, or in ovo) that evaluated cardiac defects
ith TCE (or metabolite) exposures and that had been published
ince January 2010.
The epidemiological and toxicological studies that had been
onsidered in the 2011 TCE document [87] and the new studies
hat were identiﬁed were evaluated for study quality in a trans-
arent and consistent manner, utilizing multiple reviewers with
elevant expertise. Study strengths were identiﬁed. The epidemio-
ogical studies were examined in detail for considerations of bias,
onfounding, and chance. Study ﬂaws, inadequacies, and limita-
ions were described for the toxicological studies. These analysesicology 65 (2016) 321–358 355
formed the basis for characterizing uncertainties in the epidemio-
logical and toxicological databases.
Several epidemiological studies observed evidence of an asso-
ciation between TCE exposures and CHDs. This was found to
be coherent with broader epidemiological literature reporting an
association between maternal occupational exposure to degreas-
ing solvents or organic solvents and cardiac defects. The available
database of epidemiologic studies provided some support for an
association but is not sufﬁcient to establish a causal link.
Evaluation of the toxicological data included targeted attention
given to studies and issues that have been portrayed as controver-
sial in the published literature. This was particularly in regard to
the ﬁndings of cardiac defects identiﬁed by Dawson et al. [20] and
Johnson et al. [51]. A number of potential concerns associated with
these studies were dispelled, e.g., that inadequate or inappropri-
ate cardiac evaluation methods were used, control animals were
not on study concurrently with treated animals, fetuses were not
randomly assigned to evaluations, cardiac examinations were con-
ducted with knowledge of treatment group, and statistical analysis
of cardiac malformation data was  inappropriate. Detailed compar-
isons of methods used in the various developmental toxicology
studies to evaluate potential cardiac defects helped to facilitate this
analysis as well as to identify differences between the studies that
found cardiac defects with TCE exposures [51,20] and similarly-
conducted studies that did not [15,28]. The detailed methodological
evaluation led to the conclusion that differences in study methods
(e.g., route of exposure, vehicle, animal source or strain, or other fac-
tors) may  have contributed to differences in the detection of cardiac
malformations, an issue that can no longer be deﬁnitively resolved.
As noted previously in the 2011 TCE document [87], some limita-
tions of these studies were found to be unresolvable, yet resulting
uncertainties were not judged to compromise the use of the studies
for hazard characterization and dose-response assessment.
4.2. Expanded consideration of the mechanistic database
Mechanistic data were considered as part of the WOE  analy-
sis for the 2011 TCE assessment [87]. However, those data did not
provide a linkage to the developmental pathways and processes
responsible for observed cardiac defects. Further consideration
of data identiﬁed in the literature search and the MGI  database
motivated exploration of the potential for identifying a prelim-
inary conceptual model of an AOP framework. It was proposed
that an AOP anchored to the primary dysmorphologies associated
with gestational TCE, DCA, and TCA exposure (i.e., valvulo-septal
defects, muscular and membranous ventral septal defects, and
pulmonary and aortic stenosis) might identify key events and rela-
tionships. In this construct, the vulnerable period is deﬁned by
endocardial morphogenesis. Endothelial–mesenchyme transition
(EMT) is disrupted in the area of the atrioventricular canal, lead-
ing to septal defects. Studies in knockout mice have suggested the
possible disruption of genetic signals and response by TCE expo-
sure during cardiac development. Candidate genes have implicated
pathways such as TGF-beta signaling, ephrin signaling, Notch sig-
naling, the VEGF pathway, and RXR signaling. Potential molecular
initiating events may  involve a cellular initiation of vascular inﬂam-
matory signals, perhaps through an LXR/RXR-mediated effect on
cholesterol homeostasis, vulnerability to reactive oxygen species
or disruption of the downstream consequences of VEGF signal-
ing. Although these hypothetical initiating events have not yet
been experimentally investigated, the disruption of EndMT is well-
supported as a potential key event in valvulo-septal defects induced
by TCE exposures. Even at this preliminary stage of AOP develop-
ment, the potential construct provides support for the biological
plausibility of TCE exposures resulting in cardiac defects, and it
is a signiﬁcant achievement in deﬁning research needs. Further
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esearch can provide opportunities to improve understanding of
he mechanism, including exploring linkages between proposed
OPs for molecular targets and cellular processes underlying early
eart development, and using alternative experimental models and
ethods to evaluate effects of TCE and its metabolites.
.3. Documentation of the WOE  evaluation (evidence integration)
A structured approach to the WOE  evaluation for both epidemi-
logical and toxicological hazard was conducted according to the
recepts of a published EPA evidence integration framework [86]
hat is based upon criteria established by Hill [43]. The hypothesis-
ased evidence for stronger and weaker weight of association was
ummarized and evaluated.
Overall, the WOE  supported the conclusion that TCE exposure at
ufﬁcient doses during prenatal development has the potential to
ause cardiac defects in humans. In Johnson et al. [51], the lowest
ose to rats that resulted in these outcomes was 0.048 mg/kg-day
CE in drinking water.
This conclusion is based upon multiples lines of evidence:
Epidemiological studies that identiﬁed a clear association
between cardiac defects and maternal TCE exposures via vapor
intrusion [29] and limited evidence for an association of TCE, or
TCE in combination with other solvents, in drinking water (Bove
[8]/Bove et al. [9]).
Toxicology studies with TCE from one laboratory [51,20] that
identiﬁed treatment and dose-related defects in cardiac devel-
opment in rats following maternal drinking water exposures,
although study design and reporting deﬁciencies were noted, and
other laboratories were unable to replicate the ﬁndings using
different routes of exposure [15,28].
Toxicology studies with metabolites of TCE from two  laboratories
that observed defects in cardiac development in rats after mater-
nal high-dose gavage or drinking water exposure to DCA [79,27]
or TCA [78,49].
In ovo studies from two laboratories [72,23,24,57] that found
defects in cardiac structure or function in chicken embryos result-
ing from low-dose TCE exposures that disrupted valvulo-septal
development (a process highly conserved across species, includ-
ing humans)
In vitro assays (whole embryo culture studies) from two laborato-
ries that identiﬁed alterations in cardiac development with high
doses of TCE [60] or its metabolites DCA and TCA [44] exposures
to chicken or mouse embryos, respectively.
Mechanistic data, including a putative AOP construct, that is con-
sistent with the potential for TCE to cause cardiac defects and
supports the biological plausibility of an effect on cardiac devel-
opment with exposure to TCE.
The evidence was characterized as “Sufﬁcient Experimental Ani-
al  Evidence” and “Limited Human Evidence” in accordance with
he Guidelines for Developmental Toxicity Risk Assessment [85].
.4. Extended characterization of the dose-response modeling
The dose-response relationship for cardiac defects in the John-
on et al. [51] study is robust and statistically signiﬁcant. The study
esign is unusual when compared with standard guideline devel-
pmental toxicology protocols. Treated and concurrent control
nimals were evaluated over a 6-year period, there was  a temporal
ap between the 2 lower dose groups and the 2 higher dose groups.
he possibility of increased variability among litters due to tempo-
al drift and perhaps other factors across time (overdispersion), was
ealt with by using a standard method for clustered data. The dose-
esponse trend was found to be highly signiﬁcant after adjusting
[
[xicology 65 (2016) 321–358
for overdispersion. Because the maximal observed response was
10%, models with plateaus of less than 100% were investigated and
were found to not substantially change the general conclusions and
results. Conﬁdence in the dose-response relationship is supported
by the increasing trend in response and by metabolite studies that
demonstrate ﬁndings at higher dose levels. Despite uncertainties in
the dose-response analysis, the use of the Johnson et al. [51] study
for dose-response assessment remains a reasonable choice.
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